INVITED REVIEW
Myofibroblasts. I. Paracrine cells important in health and disease

D. W. Powell, R. C. Mifflin, J. D. Valentich, S. E. Crowe, J. I. Saada, and A. B. West

University of Texas Medical Branch at Galveston, Departments of Internal Medicine, Physiology, and Biophysics and Pathology, Galveston, Texas 77555


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

Myofibroblasts are a unique group of smooth-muscle-like fibroblasts that have a similar appearance and function regardless of their tissue of residence. Through the secretion of inflammatory and anti-inflammatory cytokines, chemokines, growth factors, both lipid and gaseous inflammatory mediators, as well as extracellular matrix proteins and proteases, they play an important role in organogenesis and oncogenesis, inflammation, repair, and fibrosis in most organs and tissues. Platelet-derived growth factor (PDGF) and stem cell factor are two secreted proteins responsible for differentiating myofibroblasts from embryological stem cells. These and other growth factors cause proliferation of myofibroblasts, and myofibroblast secretion of extracellular matrix (ECM) molecules and various cytokines and growth factors causes mobility, proliferation, and differentiation of epithelial or parenchymal cells. Repeated cycles of injury and repair lead to organ or tissue fibrosis through secretion of ECM by the myofibroblasts. Transforming growth factor-beta and the PDGF family of growth factors are the key factors in the fibrotic response. Because of their ubiquitous presence in all tissues, myofibroblasts play important roles in various organ diseases and perhaps in multisystem diseases as well.

platelet-derived growth factor; stem cell factor; transforming growth factor-beta ; wound repair; fibrosis; inflammation; immunophysiology


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

A GROWING BODY OF LITERATURE over the last decade has made it evident that there is phenotypic heterogeneity among fibroblasts and that some express features of smooth muscle differentiation (73, 136, 214, 216). These smooth-muscle-like cells, or myofibroblasts as they were termed by Gabbiani (82, 83) who pioneered this field, take part in the growth, development, and repair of normal tissue as well as the diseases affecting many different organs. These cells belong to a unique class, and, even allowing for specific functions for those cells in a given organ or tissue, there is an amazing similarity in their morphology, function, and biochemical repertoire regardless of their location. Nonetheless, in a given tissue, they may express some specific appearances and functions, i.e., phenotypic and functional heterogeneity. Because of this propensity and their location next to epithelial or parenchymal cells, we have suggested they might be termed "juxtaparenchymal cells" (247).

In this review, we give an overview of myofibroblasts, illustrating similarities and differences in their biochemical/physiological/immunologic properties, and we indicate the role that these cells play in specific disease states. The major soluble factors secreted by these cells are discussed, and important receptors on myofibroblasts are listed. We have slanted the discussion toward the intestinal myofibroblasts (247): the interstitial cells of Cajal (ICC) and the subepithelial intestinal myofibroblast. This review is not meant to be entirely comprehensive of the field of myofibroblasts. It focuses on recently discovered information about the interactions of myofibroblasts with epithelial and parenchymal cells and the molecules that mediate these interactions. Furthermore, we have purposely referenced review articles when possible to amplify the reference base.


    ROLES IN HEALTH AND DISEASE
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

Table 1 lists various tissue myofibroblasts and what is thought to be their normal function. Some of these functions are well proven, and others can be inferred from the known properties of myofibroblasts in other tissues. In general, there are several common normal activities of myofibroblasts. First, through mesenchymal-epithelial interactions, myofibroblasts are key components of organogenesis or morphogenesis, i.e., the growth and differentiation of the tissue or organ (227). They do so through the secretion of soluble mediators of inflammation and growth factors (Table 2) and expression of their receptors (Table 3) and through secretion and formation of interstitial matrix and/or basement membrane molecules (Table 4) (20, 73, 82, 247). Myofibroblasts also play a fundamental role in many disease states, either through activation and proliferation or through deletion (Table 5) (51, 214, 216). They play a central role in wound healing, presumably as an extension or accentuation of their role in normal growth and differentiation (82, 83, 99, 120, 136). They appear to be involved in the formation and repair of the extracellular matrix (ECM) and proliferation and differentiation of epithelial (or parenchymal), vascular and neurogenic elements (50, 215, 250, 262).

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Myofibroblasts: possible functions


                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Cytokines, growth factors, and inflammatory mediators secreted by myofibroblasts


                              
View this table:
[in this window]
[in a new window]
 
Table 3.   Receptors expressed by myofibroblasts


                              
View this table:
[in this window]
[in a new window]
 
Table 4.   Matrix molecules important in growth differentiation and wound repair


                              
View this table:
[in this window]
[in a new window]
 
Table 5.   Tissue myofibroblasts: diseases

Healing is facilitated by the fact that the myofibroblasts are contractile, which aids in reducing the amount of denuded surface area of wounded tissue (163, 192, 242). An extension of this contractile capability allows these cells to participate in the ejection of fluid from the gastric glands (237) and in the motility of intestinal villi (120). Their relationship to myoepithelial cells, which have this function in the breast lobule (204) and the seminiferous tubules of the testis (106), is unclear. The contractile property of pericytes and specialized pericytes such as the hepatic stellate (Ito) cell, the mesangial cell of the kidney, and the glomus cell of peripheral vessels gives these myofibroblasts the ability to locally autoregulate blood flow (122, 124, 160, 177, 216, 247). The ability to accumulate and extrude calcium causes cyclic increases and decreases in calcium concentration in these cells, permitting actin-myosin contraction (77). This process is probably the same as or similar to the one responsible for the ability of the ICC to perform a pacemaker function in the intestine (212). Because myofibroblasts are interconnected through gap junctions (120, 212, 246), the electrical signals created by cyclic ion movements can be transmitted through the syncytium and thus through the length of the resident organ.

Myofibroblasts play a major role in the inflammatory response. These cells are avid producers of both chemokines and cytokines (105, 178, 179, 227, 235, 267) and are capable of augmenting or downregulating the inflammatory response by the secretion of these soluble mediators of inflammation (Table 2). They also synthesize prostaglandins, expressing both the constitutive cyclooxygenase-1 (COX-1 or PHS-1) gene product and the inducible COX-2 (PHS-2) protein (19, 69, 102, 105, 167, 240, 241, 259). In some tissues they make both nitric oxide and carbon monoxide, gases known or proposed to be important neurotransmitters and regulators of motility and inflammation (1, 14, 39, 69, 162, 167, 202, 240, 241). When activated, myofibroblasts also express adhesion molecules such as intracellular adhesion molecule-1, vascular cell adhesion molecule, and neural cell adhesion molecule (100, 133, 151, 178, 192). Thus lymphocytes, mast cells, and neutrophils may dock on the myofibroblasts and participate in organized immunological and inflammatory reactions (31, 48, 67, 105, 201, 236). Myofibroblasts also express alpha  and beta  integrins that are part of the adhesion mechanism of myofibroblasts to matrix proteins (192). Through these or other properties, myofibroblasts participate in the formation of tissue granulomas (208, 247). Granulomas themselves are impressive factories of cytokines and other inflammatory mediators (87, 114).

Last, production of matrix molecules such as collagen, glycosaminoglycans, tenascin, and fibronectin in the interstitial space or basement membrane (Table 4) is part of the structure, growth, differentiation, and wound healing function of myofibroblasts (20, 227). These processes, when unchecked, deranged, or repeated, can result in tissue fibrosis (4, 25, 71, 72, 88, 138, 150). Therefore, fibrotic disease is a major pathological end point of activated and proliferating myofibroblasts in most, if not all, tissues.

Disease states not mentioned in Table 3 are inflammatory pseudotumors of the lung, liver, or stomach (64) and neoplastic transformation of the myofibroblasts themselves. Recent evidence indicates that stromal tumors of the gastrointestinal tract are derived from c-kit mutations in gastrointestinal myofibroblasts (103). Another benign neoplasm of myofibroblasts is the desmoid tumor, which can occur in any tissue but develops most commonly in the mesentery of the gut (92). Although desmoids can and do occur sporadically, they are particularly common (increased 850 times) in the familial adenomatous polyposis (FAP) syndrome. FAP is a hereditary malignancy presenting as colonic polyps and colorectal carcinoma (233) that is due to mutations in the adenomatous polyposis coli gene (92). Malignant myofibroblasts are also observed in clearly aggressive tumors such as angiosarcomas, fibrosarcomas, histiocytomas, and mesotheliomas (46, 216). Myofibroblasts are also responsible for the desmoplastic reaction seen in many cancers, i.e., the proliferation of fibrotic tissue within or adjacent to the tumor itself. This is most often observed in breast carcinoma, carcinoid tumors, Hodgkin's disease, and malignant melanomas (70, 153, 204, 218, 264). The role of myofibroblasts in both hereditary and nonhereditary colon cancer is discussed in more detail later in part II of this review [which will appear in the August issue (191)] (see also Ref. 131).


    DEFINITION OF A MYOFIBROBLAST
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

Myofibroblasts may be defined morphologically and immunologically through identification of expressed cytoskeletal proteins (214, 216). The simplest definition of a myofibroblast is that they are smooth-muscle-like fibroblasts. Some investigators choose to call them smooth-muscle-like cells or activated smooth muscle cells (159, 163, 237). Others refer to them as lipocytes because of their propensity to store retinoids (vitamin A) or as stellate cells, because of a shape change of transiently differentiated myofibroblasts (see below). Myofibroblasts may well represent an intermediate state between fibroblasts and smooth muscle cells. This is best demonstrated in the prostate (98, 125, 181), in the pericytes surrounding the fetal vessels of the placental stem villus (134), and in the stromal myofibroblasts of the breast (204).

In both cell culture in vitro and native tissues in situ, myofibroblasts possess several distinguishing morphological characteristics, some of which are present in fibroblasts or smooth muscle cells (Fig. 1). They display prominent cytoplasmic actin microfilaments (stress fibers), and they are connected to each other by adherens and gap junctions (51, 239). These cells are also in contact with the ECM by focal contacts once known as the fibronexus, a transmembrane complex made up of intracellular contractile microfilaments and the ECM protein fibronectin (65). Both fibronexus formation and stress fiber assembly are regulated by Rho, a newly described member of the RAS superfamily of small guanosine triphosphatases (GTPases) (94), specifically in mammalian cells by Rho A. These small, monomeric GTP-binding proteins also regulate myofibroblast morphology (191, 265). Often, an incomplete basal lamina surrounds the myofibroblasts. Gap junctions couple some myofibroblasts to the tissue smooth muscle, and the cells are commonly in close apposition to varicosities of nerve fibers (134, 212, 243).


View larger version (144K):
[in this window]
[in a new window]
 
Fig. 1.   A: transmission electron micrograph of a cultured lumen intestinal subepithelial myofibroblast (18Co). The cell membrane displays numerous caveolae. Stress fibers (bundles of actin microfilaments) are prominent. The cytoplasm is rich in rough endoplasmic reticulum, Golgi apparatus, and mitochondria. B: nucleus of an activated myofibroblast shows multiple indentations. Adherens (C) and gap junctions (D) are present between myofibroblasts. [From Valentich et al. (246).]

In some tissues, e.g., the liver (Ito cells) (88), intestine [both the ICC (243) and the subepithelial myofibroblasts] (78, 246), the orbital myofibroblast (195, 254), the synoviocyte of the joint space (11), and brain (astrocyte) (15, 166, 193), the myofibroblasts exist in two distinct morphological states (Fig. 2): 1) the "activated" myofibroblast, as described above, and 2) the stellate-transformed myofibroblast, which is considered to be a transiently differentiated myofibroblast. This generalization, correlating appearance and function, has not been verified in every tissue where such morphological heterogeneity has been seen. Agents (e.g., prostaglandins, cholera toxin, vasoactive intestinal polypeptide) that increase the cAMP content of activated myofibroblasts and cell-soluble cAMP analogs themselves induce stellate transformation in vitro within 24 h (78) and stop myofibroblast proliferation (5, 119).


View larger version (181K):
[in this window]
[in a new window]
 
Fig. 2.   Phase-contrast micrographs (A and B) and scanning electron micrographs (C and D) of stellate 18Co cells. The stellate myofibroblast displays a highly refractile cell body on phase-contrast microscopy and possesses a highly arborized array of cell processes with several orders of bifurcation. The cell processes are devoid of microvilli, whereas the cell body shows a dense array of long microvilli, giving it a shaggy appearance. [From Valentich et al. (246).]

Immunohistochemical characterization of myofibroblasts is based on antibody reactions to two of the three filament systems of eukaryotic cells (75, 116). These three systems are composed of 1) actin, a component of the microfilaments; 2) vimentin, desmin, lamin, or glial fibrillary acidic protein (GFAP), members of the intermediate filament system; and 3) the tubulins of the microtubules. Myofibroblasts have not been characterized with regard to tubulins. The beta  and gamma  actins are expressed by all cells, including myofibroblasts, which may also express alpha -smooth muscle (alpha -SM) actin (214, 216). Myofibroblasts stain negatively for alpha -cardiac and alpha -skeletal actin (216). Myofibroblasts are not well characterized with regard to the newly defined myosin isoforms (75, 161, 217). In some tissues, such as the intestine and reticular cells of lymph nodes and spleen, myofibroblasts stain positive for smooth muscle heavy chain myosin or tropomyosin (old terminology) (216, 243).

Vimentin, desmin, and alpha -SM actin are the three filaments most often used to classify myofibroblasts (161). Expression of these proteins may vary with the tissue studied within species and is subject to environmental factors, e.g., whether the cells are studied in situ or in culture and, even within a given tissue, whether the cells are activated by hormonal or cytokine treatment or by disease (191). Based on immunohistochemical staining of these filaments in a given tissue, a classification system has been proposed (134, 216). Myofibroblasts that express only vimentin are termed V-type myofibroblasts, those that express vimentin and desmin are called VD-type, those that express vimentin, alpha -SM actin, and desmin are called VAD-type, those that express vimentin and alpha -SM actin are called VA-type, and those that express vimentin and myosin are called VM-type.

In the intestine, the ICC express immunoreactive vimentin, gamma -SM actin, and smooth muscle tropomyosin, suggesting that they are members of the V or VM (243) class of myofibroblasts. However, we have not been able to find references indicating that ICC have been explored with antibodies to alpha -SM actin. The intestinal subepithelial myofibroblasts (ISEMFs) stain positive for vimentin and alpha -SM actin and negative (or weakly) for desmin (VA-type). They also express smooth muscle myosin (thus may be called VAM-type myofibroblasts), although expression of myosin is less than that seen in corresponding smooth muscle cells in the same tissue (120, 153, 246). It is possible that both intestinal myofibroblasts, the ICC and ISEMF, could be the VA(M)-type.

Specific monoclonal antibodies have been developed to identify myofibroblasts in certain tissues. For example, the monoclonal antibody Gb42 recognizes placental myofibroblasts (134). The 8E1 monoclonal antibody reacts with many of the stellate-shaped myofibroblasts, such as GFAP-positive astrocytes, and both intestinal myofibroblasts, the ICC and ISEMF (79). Anti-GFAP serum stains astrocytes, pancreatic periacinar stellate cells, and hepatic stellate (Ito) cells (30). The PR2D3 antibody stains subepithelial myofibroblasts in the stomach and intestine, lung myofibroblasts, periductular myofibroblasts of the kidney, testes, and breast, Ito cells of the liver, umbilical cord stellate myofibroblasts, and both vascular and tissue smooth muscle of most organs (199). Antibodies against the protooncogene c-kit, the receptor for stem cell factor (SCF or steel factor), react with ICC (109, 132, 244) and possibly with pulmonary alveolar myofibroblasts (61). No systematic studies have been reported concerning the reactivity of all the other myofibroblasts to c-kit antibodies.

In many of the studies quoted above, only a subset of the (myo)fibroblasts stain with alpha -SM actin antibodies in vivo or in vitro (culture). In vivo, not all fibroblastic-appearing cells are myofibroblasts. In culture, treatment with transforming growth factor-beta (TGF-beta ) may induce uniform alpha -SM actin staining of all the cells, providing the cells are of a single clone (226). Furthermore, activation to an alpha -SM actin-expressing phenotype may require both TGF-beta and a specific cell-matrix interaction (118, 222) (see ACTIVATION, PROLIFERATION, AND MIGRATION OF MYOFIBROBLASTS).


    ORIGIN OF MYOFIBROBLASTS AND ROLE IN GROWTH AND DEVELOPMENT
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

It is unclear whether myofibroblasts originate from progenitor stem cells (possibly neuroepithelial stem cells) (24, 157) from the neural crest (117) or simply transdifferentiate from resident tissue fibroblasts (81) or from tissue (e.g., vascular, intestinal, or uterine) smooth muscle cells (204). The close anatomic relationship of pericytes to vascular smooth muscle and of intestinal myofibroblasts to intestinal smooth muscle suggests a bidirectional route of transdifferentiation. These various possibilities are depicted in Fig. 3. It has recently been suggested that renal tubular cells (a cell of endoderm origin) might differentiate into myofibroblasts (mesenchymal cells) under noxious stimuli (171, 177, 198). However, it is equally likely that the peritubular interstitial myofibroblasts are proliferating under these circumstances and simply replacing apoptotic tubular cells in these disease states.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Proposed scheme depicting the origin, transdifferentiation, activation, and stellate transformation of myofibroblasts. PDGF, platelet-derived growth factor; TLP, tethered ligand protein; TGF-beta , transforming growth factor-beta ; IL-1, interleukin-1; EGF, epidermal growth factor; bFGF, basic fibroblast growth factor; IGFI, insulin-like growth factor I; CTGF, connective tissue growth factor.

Two soluble factors have been shown to promote differentiation from embryonic stem cells: PDGF and SCF. PDGF has two chains, A and B, and exists as a homodimer (PDGF-AA or PDGF-BB) or as a heterodimer (PDGF-AB). Each form acts on separate receptors: alpha  receptors that are nondiscriminatory and can bind AA, BB, and AB dimers or beta  receptors that are specific for the B chain (126). After ligand binding, there are two separate intercellular signaling pathways for the PDGF receptor: a mitogen-activated protein kinase (MAPK) path and one involving phosphatidylinositol 3-kinase (PI3K). Depending on the cell types, one pathway may be required for cell activation and/or proliferation and the other pathway for cell motility (migration) (3, 72, 150). For example, smooth muscle cells proliferate in response to the MAPK cascade and migrate in response to the PI3K path, whereas hepatic stellate cells and endothelial cells respond with both proliferation and migration via the PI3K (72).

Disruption of the PDGF-AA gene in mice is lethal in 50% of affected animals (26). The surviving animals are almost completely devoid of lung alveolar myofibroblasts (also called pulmonary contractile interstitial cells) and develop emphysema due to failure of lung septation. In contrast, animals born with disruption of the PDGF-BB gene have a virtual absence of renal mesangial cells and failure of the formation of the complex structure of the glomerulus (141, 234). The PDGF-BB-deficient animals also lack pericytes and thus develop microaneurysms, reminiscent of those seen in the diabetic retina, and leaky vessels that cause tissue edema and hemorrhage (142). Intestinal subepithelial myofibroblasts (119) and hepatic stellate cells (147) proliferate in response to low concentrations of PDGF-BB, suggesting that this growth factor is important in the growth and development of these cells.

The protooncogene c-kit is the transmembrane glycoprotein tyrosine kinase (III) receptor (160 kDa molecular mass) for SCF, a growth factor secreted by epithelial cells, white blood cells, and (myo)fibroblasts. SCF is also a member of the PDGF family, and the tyrosine kinase type III family also includes receptors for granulocyte/macrophage colony-stimulating factor (GM-CSF). Intestinal ICC (in situ and in culture) express c-kit as detected by rat anti-kit (ACK2) monoclonal antibodies (18, 109, 132, 174, 244). Mutations in the c-kit locus, the W mutants, result in abnormalities in the number, structure, and function of the ICC (18, 52, 174, 212, 249). Furthermore, mutants of the ligand SCF, steel (Sl) mutants, also show morphological and functional abnormalities of the ICC (257). Thus the PDGF family of growth factors seems crucial for the embryological development of myofibroblasts. Unfortunately, no systematic study of the various different tissue myofibroblasts has been reported in PDGF or SCF knockout mice or in mutants of their respective receptors.

TGF-beta , PDGF, insulin-like growth factor II (IGF-II), and interleukin-4 (IL-4) appear to be the most important growth factors for the transdifferentiation of fibroblasts to myofibroblasts or of stellate-transformed myofibroblasts into activated myofibroblasts (45, 61, 145, 211, 239). When myofibroblasts from the intestine (74), breast (203), skin (17, 111, 263), liver (88), lung (214), prostate (181), nose (256), and joint synovium (214) are treated with TGF-beta in serum-containing media, they express alpha -SM actin, reduce the number of vitamin A lipid droplets, and expand the rough endoplasmic reticulum, i.e., they take on the morphology of an activated myofibroblast. Conversely, interferon (IFN)-alpha and IFN-gamma (56, 90) decrease the expression of alpha -SM actin in myofibroblasts. It is not clear whether they do so by transdifferentiating myofibroblasts back to the fibroblast state, inducing them to undergo stellate transformation, or simply downregulating the amount of alpha -SM actin in the cell.


    ACTIVATION, PROLIFERATION, AND MIGRATION OF MYOFIBROBLASTS
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

Fibroblasts or stellate-transformed myofibroblasts become activated and proliferate when cultured on plastic in serum-containing growth culture media, especially when seeded at low cell density (74, 155). In vivo activation, as signified by the development of alpha -SM actin positivity, may be separable from proliferation. Whereas many fibrogenic cytokines [IL-1, tumor necrosis factor (TNF)-alpha , PDGF, fibroblast growth factor (FGF), and TGF-beta ] have been incriminated in this process (138), TGF-beta appears to be the most important cytokine causing the development of alpha -SM actin staining and an activated phenotype (25, 45, 88, 97, 155, 165, 223, 238) capable of collagen secretion (25, 45, 165). The source of TGF-beta in damaged tissue may be from white blood cells, parenchymal or epithelial cells, or from the myofibroblast itself in an autocrine fashion (22, 25, 45, 88). Recently, it has been determined that the activation of the myofibroblast requires the presence of matrix molecules, specifically, the ED-A (EIIIA) domain of fibronectin (118, 222). Tissue injury gives rise to this specific ED-A domain splice variant of fibronectin. ED-A is the binding site for cell membranes and for other matrix molecules. It has been shown in both skin granulation tissue (222) and hepatic (118) models that this fibronectin ED-A domain is necessary for TGF-beta to trigger alpha -SM actin expression and collagen secretion by myofibroblasts. Following activation of the myofibroblast, PDGF or connective tissue growth factor (CTGF), a member of the PDGF family (29), appears to be the factor primarily responsible for myofibroblast proliferation (71, 72, 89, 119, 147). TGF-beta was once considered the prime factor (88, 214, 216), but it is now thought that TGF-beta acts predominantly through the induction of PDGF receptors on or synthesis of CTGF by the myofibroblasts (72, 89, 111, 112, 263). Thus TGF-beta is predominantly a cytodifferentiating rather than a proliferating growth factor.

The TGF-beta s are a large superfamily of soluble factors important in growth, development, and fibrogenesis (149). TGF-beta 1, TGF-beta 2, and TGF-beta 3 are encoded from three separate genes. TGF-beta 1 is the isoform usually upregulated in the presence of tissue injury. It is secreted in a latent form after cleavage from a large promolecule and then noncovalently binds to another peptide on the cell membrane called the latency-associated peptide, which, in turn, is formed from the cleavage fragments of the TGF-beta precursor. This latent TGF-beta is stored on the surface of the cell or on the extracellular matrix, awaiting conversion by unknown mechanisms to active TGF-beta . In contrast to their apparent (but probably indirect) proliferative effect on myofibroblasts (see above), TGF-beta s cause G1 phase cell cycle arrest of epithelial and smooth muscle cells and may even induce apoptosis (25). TGF-beta acts through a superfamily of serine-threonine kinase cell surface receptors. All three TGF-beta s bind first to the type II (RII) receptor that assembles and phosphorylates the type I (RI) receptor, activating this serine-threonine kinase and transducing the signal (25). Microsatellite (genomic) instability due to defects in DNA mismatch repair systems of the TGF-beta receptors has been incriminated in the unregulated growth of cancer and in vascular atherosclerosis/restenosis (159). This raises the question of a role for myofibroblasts in these two diseases [see part II of this review (191)].

TGF-alpha (138), a member of the epidermal growth factor (EGF) family, as well as EGF itself (138, 214, 216, 226), GM-CSF (25), both acidic and basic FGF (aFGF and bFGF, respectively) (25, 119, 185, 214, 216, 226), and IGF-I and IGF-II (25, 226) are candidate growth factors promoting myofibroblast proliferation (see more details in Growth Factors). Proinflammatory cytokines such as TNF-alpha , IL-1, IL-6, and IL-8 may also cause activation and proliferation (119, 138, 177, 185, 246) as does IL-4, a protein generally thought of as an anti-inflammatory cytokine (61, 156, 211).

ANG II or aldosterone, thrombin, and endothelin are also important soluble factors reported to promote myofibroblast activation (15, 34, 35, 77, 246, 258). Endothelin is capable of rapidly transdifferentiating the stellate morphology of intestinal myofibroblasts to the activated phenotype within 30 min of addition to cell culture media (78, 80, 246). After it activates the myofibroblasts, endothelin may subsequently inhibit their proliferation (147, 148).

Cocultures of fibroblasts and myofibroblasts with cancer cells of several different types induce transdifferentiation of fibroblasts to myofibroblasts and activation and proliferation of myofibroblasts (13, 19, 46, 70, 136, 149, 153, 204, 246, 264). This property of neoplastic cells, perhaps via secretion of growth hormones such as TGF-beta , may well be responsible for the desmoplastic reaction (excessive fibrosis) seen in many cancers.


    ROLE IN WOUND REPAIR
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

The process of wound healing is a highly orchestrated event that entails the release of proinflammatory cytokines, eicosanoids of the cyclooxygenase, lipoxygenase, and cytochrome P-450 family, nitric oxide, and a host of growth factors; the secretion of collagen and other matrix proteins; the elaboration of angiogenic, angiostatic, and nerve growth factors; and, finally, if it is a deep or open wound, the formation of granulation tissue that then becomes a scar (fibrosis) (20, 57, 187, 208, 214, 247, 252). Myofibroblasts appear to be key cells in these various events. They become activated and proliferate in the early stages of wounding. They respond to proinflammatory cytokines with elaboration of matrix proteins and additional growth factors and then disappear by apoptosis following repair or scar formation (51, 54, 55, 113, 164, 266).

Repair Processes

Epithelial tissues such as the intestine or stomach, in contrast to organs such as the liver, kidney, or lung, do not commonly sustain widespread injury that leads to uniform fibrosis. However, gastrointestinal epithelial tissues are often superficially injured. In fact, exfoliation of the epithelium is viewed as a defense response to certain noxious insults such as toxins, microbiological invasion, or gut anaphylaxis (163). The process of repair of the epithelium occurs through two separate mechanisms (252). If the basement membrane underlying the sloughed epithelium is intact, residual epithelial cells at the edges of the wound become motile and move along the basement membrane until they meet advancing epithelial cells from the other side of the wound and form new tight junctions. This process is called restitution (189, 225). Prostaglandins from COX-1 or COX-2 activation are key factors promoting restitution (23) and preserving the epithelial cells from damage (47). Myofibroblast-secreted growth factors such as TGF-beta , TGF-alpha , EGF, aFGF, and bFGF and inflammatory cytokines such as IL-1beta and IFN-gamma also promote restitution (58, 59, 189, 190, 200).

Conversely, if the wound is deep, the subepithelial tissues that contain interstitial substance, blood vessels, nerves, and fibroblasts must be reconstituted. If the basement membrane has been destroyed by the noxious stimulus, epithelial cells and mesenchymal elements form a new basement membrane (252). Epithelial stem cells then undergo mitosis and proliferate and migrate along the newly formed basement membrane. This latter process is a coordinated event involving secretion of matrix proteins and growth factors. Thus myofibroblasts appear to play roles both in the restitution and repair processes.

A key event in the process of wound repair by either restitution or proliferation is contraction of the underlying granulation tissue or gastrointestinal lamina propria to limit the exposed surface area of the wound (51, 120, 163, 192, 208, 242). Myofibroblasts contain smooth muscle myosin isoforms in addition to alpha -SM actin, the requisite machinery for contraction and/or motility. The ability of myofibroblasts to carry out these processes depends on changes in the cellular cytoskeleton as well as in the Rho-regulated fibronexus and on the expression of integrins that allow attachment of the myofibroblasts to the extracellular matrix (192, 242).

The fibronexus, discovered and characterized by Eyden (65) and Singer and colleagues (228-232) connects the myofibroblast to the extracellular matrix through a transmembrane alpha beta integrin complex that joins the actin stress fiber of the myofibroblast to ECM fibronectin (32, 192). The Rho family of small GTPases includes Rac 1-3, Cdc 42, and Rho A-H, which respond to PDGF, TNF-alpha or bradykinin, or lipopolysaccharide A, respectively. In mammals, Rho A acts on the actin cytoskeleton to cause myofibroblast shape change or motility (6, 265).

ECM

The ECM is a complex mixture of collagen, other glycoproteins, and proteoglycans distributed in each organ or tissue in unique proportions (220, 227). These matrix proteins have several general functions: they are the scaffold for tissue formation and growth; through binding to cell receptors (integrins), they initiate intercellular signaling events; and they bind to growth factors and thus supply sustained concentration of these factors for epithelial or parenchymal cell migration, proliferation, and differentiation (20, 219, 227). There are at least 19 different collagens in the collagen superfamily, with types I, III, IV, and VIII being secreted by myofibroblasts (154, 168). Proteoglycans are proteins with large sulfated polysaccharide side chains of several types (Table 4). The major glycoproteins secreted by the myofibroblasts are the various laminins, which include fibronectin (see ACTIVATION, PROLIFERATION, AND MIGRATION OF MYOFIBROBLASTS) and tenascin. Laminin is a constituent of the basement membrane along with type IV collagen, entactin, and chondroitin sulfate (all of mesenchymal origin) and perlecan, a large, low-density proteoglycan composed of heparan sulfate side chains of epithelial cell origin (20, 227). Basement membranes and matrix are degraded by a family of Zn2+-dependent matrix metalloproteinases (MMPs 1-3) also secreted by myofibroblasts (146, 251). They are classified by the substrates they degrade: MMP 1 digests types I, II, and III collagen; MMP 2 (gelatinase A) digests denatured collagens I and III and native collagen IV; and MMP 3 (stromelysin) degrades laminin, fibronectin, proteoglycans, type IV collagen, and casein (16, 251). These MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs) (16). Growth factors may bind to heparan sulfate proteoglycans or collagen, thus controlling their availability both temporally and spatially, and so modify their biological activity (20, 219, 227, 242).

Growth Factors

The growth factors secreted by myofibroblasts have three general functions as follows: 1) they initiate or increase cell mobility, 2) they induce proliferation, i.e., they are paracrine mitogens for epithelial or parenchymal cells and perhaps autocrine mitogens for themselves, or 3) they induce terminal differentiation of these cells, even driving the cells to apoptosis. Some growth factors seem to have all three effects.

Individual growth factors may be produced by the epithelial cells alone (trefoil proteins), by mesenchymal cells such as myofibroblasts or inflammatory cells, particularly macrophages and lymphocytes, and some by both cell types (67). Furthermore, the various inflammatory cytokines, eicosanoids, and growth factors released during tissue damage may directly affect the epithelium or parenchymal cell of the injured tissue, or these agents may act more proximally on myofibroblasts to induce these cells to secrete additional cytokines, eicosanoids, or growth factors (67). Thus an in vivo epithelial proliferative response could be the result of a cytodifferentiating effect of mediators on the myofibroblasts, inducing them to express receptors for other factors or to secrete specific epithelial proliferating growth factors. Examples of this are TGF-beta 1, which induces the expression of PDGF receptors on or CTGF secretion by the myofibroblasts, causing them to proliferate in response to PDGF (137), or the secretion of hepatocyte growth factor (HGF) or keratinocyte growth factor (KGF) by myofibroblasts in response to IL-1 (37) or immune stimulation (10, 66).

IL-1 (60), IL-6 (261), IL-15 (196), and TNF-alpha (121, 139) have also been identified as being involved in tissue repair and have been shown to be mitogenic for several mesenchymal and epithelial cell lines. Furthermore, combinations of cytokines and growth factors may have offsetting effects on epithelial proliferation, so the ultimate consequence of these various factors in vivo can be quite complicated.

Factors secreted by myofibroblasts such as EGF and TGF-alpha (12, 188), IGF-I and IGF-II (144, 145), HGF (28, 84, 173), and members of the FGF family, including aFGF, bFGF (also known as FGF-2) (110), KGF (also known as FGF-7) (107, 207), and IL-11 (38, 175, 194), have been demonstrated to be the major paracrine growth factors for epithelial and parenchymal cells. The trefoil peptides, secreted by the epithelial cells themselves, have similar effects through autocrine stimulation (186). These factors may also have nonmitogenic effects on intestinal cells as well, e.g., they may regulate secretory and contractile processes as well as regulate blood flow (245).

The trefoil peptides are so named because of a distinctive pairing of six cysteine residues that results in three interchained loops, thus giving a "three leaf" trefoil shape (38, 186). There are three such trefoil proteins that are small, highly stable molecules secreted principally by the goblet (mucus)-secreting cells of the epithelium and not by myofibroblasts. The stomach secretes peptide pS2 in the fundus and spasmolytic polypeptide (SP) in the antrum, whereas the breast epithelium secretes only pS2 and the pancreas secretes only pancreatic SP (pSP) (129). In contrast, the intestinal epithelium secretes only intestinal trefoil factor (ITF). Targeted gene disruption of ITF causes abnormal epithelial cells and increased susceptibility to various models of injury, resulting in a colitis-like picture (7, 130). Exogenous administration of ITF repairs the damage susceptibility in this knockout model and also protects the gastric mucosa against other injuries such as those induced by ethanol or chronic indomethacin administration (7). PS2 gene knockout mice have a different disease phenotype; they develop extensive neoplastic adenomas in the antrum of the stomach, which then progress to carcinoma in situ (140).

TGF-alpha , EGF, and the EGF human homologue urogastrone (EGF/URO) are members of the same family of polypeptides and act on a common cell membrane receptor (12, 188). The TGF-alpha /EGF receptor appears to be upregulated in the mucosa of injured intestine and other organs. TGF-alpha is expressed in epithelial cells, myofibroblasts, and monocytes/macrophages, whereas EGF seems to be produced primarily by the epithelial cells of the salivary gland and Brunner's glands of the duodenum. TGF-alpha is synthesized as a 160-amino acid precursor molecule that spans the cell membrane. Proteases release the soluble 50-amino acid form. It is unclear whether the membrane-bound form is active as a growth factor for adjacent cells. The soluble factor is trophic (mitogenic) for a number of cell lines in vitro and intestinal epithelial cells in vivo. It may well have differentiating functions as well. Ulceration of the human gastrointestinal mucosa causes the development of a specific cell lineage from epithelial stem cells that bud from the crypts next to an ulcer and then ramify to form a small gland. These budding glands secrete EGF/URO, which stimulates epithelial proliferation and promotes ulcer healing (260).

The FGF family (aFGF and bFGF) are important mitogens for myofibroblasts and have powerful neurotrophic and angiogenic properties that are important for tissue healing (68, 110). Other angiogenic factors secreted by myofibroblasts include the CXC family of cytokines such as IL-8 and epithelial neutrophil-activating peptide (ENA-78) (5, 127, 178). Cell-to-cell contact such as that occurring in restitution or wound healing has its antiapoptotic action via the adhesion molecule N-cadherin. When the adjacent cells touch, there is homophilic binding of N-cadherin molecules, which activate the FGF family of receptors. In this way, cell contact mimics the antiapoptotic effect of bFGF (91).

IGF-I and IGF-II are structurally related polypeptides that have various metabolic, proliferative, and differentiating effects through endocrine, autocrine, and paracrine mechanisms (144, 145). The effects are mediated by IGF-I receptors and insulin receptors. There is an IGF-II receptor, but its role in signal transduction is unclear. IGF is present in the circulation (from liver) and is also secreted in a paracrine fashion by myofibroblasts adjacent to epithelial and parenchymal cells (144). The IGF actions are determined by the availability of free IGF, the form that interacts with its receptors. In turn, the amount of free IGF is modulated by the level of high-affinity IGF-binding proteins (IGFBPs), of which six have been identified (42-44). These IGFBPs not only regulate the bioavailability of IGF but also inhibit or enhance its action on target tissues. Although the IGFs are weakly mitogenic for epithelial and parenchymal cells, they seem to be powerfully mitogenic for myofibroblasts (226) and other smooth muscle cells (255).

A new member of the family of factors stimulating epithelial growth is IL-11, a multifunctional cytokine originally derived from bone marrow stromal cells (175, 194). It regulates the growth of hematopoietic and lymphoid cells by acting on the IL-6 family of cytokine receptors. It stimulates proliferation of small intestinal crypts and accelerates recovery of the intestinal mucosa from models of damage (143). It also has trophic effects on neurons, preadipocytes, and myofibroblasts of the lung (175). TGF-beta and IL-1 are potent stimulants of IL-11 production. Paradoxically, IL-11 has been shown to inhibit epithelial cell proliferation in the lung by altering phosphorylation of the retinoblastoma protein (194). Thus it is possible that the proliferative effect of IL-11 on epithelia occurs via activation of myofibroblasts, with subsequent secretion of epithelial proliferating factors by these cells, rather than being a direct effect of IL-11 on the epithelium itself.

KGF is a member of the FGF family (FGF-7) (107, 207). This factor is unique because, unlike other members of the FGF family, it does not appear to have activity on fibroblasts, endothelial cells, or other nonepithelial targets. This is a consequence of the epithelial cell expression of the KGF receptor (KGFR), a transmembrane tyrosine kinase that binds KGF and aFGF with high affinity and binds bFGF much more poorly. The KGFR is nearly identical to the FGF receptor type II, except for alterations in a 49-amino acid residue in one of its extracellular loops. FGFR-II does not bind KGF but shows a high affinity for both aFGF and bFGF. KGFR expression is limited to epithelial cells, whereas FGFR-II is present in a variety of tissues including fibroblasts. KGF, initially isolated from lung fibroblasts, appears to be a myofibroblast-secreted epithelial growth factor with specific roles in epithelial growth and differentiation. The KGFR is expressed on the epithelial cells, and KGF has been shown to induce proliferation and differentiation of a host of epithelial and parenchymal cells, including intestinal epithelial cells, type II pneumocytes, hepatocytes, and keratinocytes of the skin. Its expression and secretion are regulated by IL-1 (37). Its synthesis is significantly upregulated in the lamina propria of inflamed intestine (66). Thus KGF represents a prime example of a mediator causing a specific mesenchymal-epithelial interaction.

HGF, also known as scatter factor because it induces cell migration as well as proliferation, is synthesized and secreted by fibroblasts and myofibroblasts (28, 84). HGF is a glycoprotein heparin-binding heterodimer related to plasminogen, consisting of a heavy alpha  chain and a light beta  chain held together by disulfide bonds (84). It is produced as a single-chain precursor protein and proteolytically cleaved to form HGF. The HGF receptor, prominently expressed by epithelial cells, is encoded by the protooncogene c-met. This receptor is a heterodimeric glycoprotein of 190 kDa linked with two disulfide bonds; the alpha  chain is extracellular, while the membrane-spanning beta  chain has the cytoplasmic domain of a tyrosine kinase. C-met also is regulated by proteases that cleave both chains from a 178-kDa common precursor. Thus HGF is only active if the correct proteases are present. Like TGF-beta , HGF has effects on cell division, motility, and apoptosis and appears to have angiogenic activity (28). Its synthesis is stimulated by IL-1 (28). Not only does it cause proliferation of epithelial cells but it also affects parenchymal cells such as liver and bone (28). Thus HGF, like KGF, is a major mediator of epithelial-mesenchymal interactions and epithelial morphogenesis (207).

The process of repair is completed by the terminal differentiation of epithelial and parenchymal cells and by apoptosis of the alpha -SM actin myofibroblasts (51, 81, 216). The factors that terminate the repair process are poorly understood. The role of IL-10, INF-gamma , and INF-alpha in either the downregulation (90, 197) of myofibroblasts or induction of their apoptosis (95, 128) needs further investigation.


    ROLE IN FIBROSIS
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

With repeated cycles of injury and repair or if, for unclear reasons, there is loss of the signals that discontinue the healing process, organ fibrosis occurs. The important functions of the myofibroblasts in the fibrosis of tissues such as the skin, lung, pancreas, and kidney are well described (see references in Table 4). The effects of PDGF, TGF-beta , and other growth factors in the fibrotic process have been studied in detail (72, 93, 167, 214, 239) and are beyond the scope of this review (see Refs. 20 and 96 for detailed reviews of fibrosis).

Factors that act on myofibroblasts are important in tissue fibrosis. Recently, the key role of TGF-beta in fibrosis has been accentuated by the finding of fibrosis of multiple organs, including the liver, kidney (both renal interstitium and glomerulus), and adipose tissue in a transgenic mouse overexpressing TGF-beta (45). PDGF-BB causes fibrosis in the kidney (239), and, given the propensity of TGF-beta to upregulate PDGF receptors, an equally important role for PDGF cannot be ruled out. IGF-I has been shown also to induce collagen mRNA and IGF binding protein-5 mRNA in rat intestinal smooth muscle (269), raising the question of an important role for this growth factor in organ fibrogenesis (268). IL-1, IL-6, INF-gamma , TNF-alpha , and bFGF have also been incriminated as fibrogenic cytokines (101, 205). Potential abnormalities in matrix secretion, degradation of matrix by MMPs, and inhibition of MMPs by TIMPs (see above) that might result in fibrosis are under investigation (21, 96, 154). An understanding of these processes and the development of effective pharmacological or biological inhibitors would be important advances in the treatment of disease.


    CONCLUSIONS AND SPECULATION
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

Myofibroblasts are ubiquitous cells with similar properties and functions that play important roles in growth and development, wound repair, and disease. Either their absence or their activation and proliferation in a given tissue or organ can lead to specific diseases as outlined in Table 3. However, because they are present in virtually every tissue, it is possible that they may play a role in multisystem diseases as well. For example, do abnormalities in pericytes account for some of the multifocal effects of chronic hypertension (208)? Are the multiple abnormalities of diabetes mellitus due to stimulation of or damage to vascular, renal, intestinal, and skin myofibroblasts? It is intriguing that high glucose concentrations induce TGF-beta 1 production by the glomerular mesangial cell (135), and PDGF and bFGF improve wound healing in genetically diabetic animals (87). What is the role of myofibroblasts in aging, a condition in which myofibroblasts are reported to be morphologically abnormal (169)? These are but a few of the intriguing questions raised by this unique family of pleiotropic cells.


    ACKNOWLEDGEMENTS

We thank Terri Kirschner for excellent editorial expertise.


    FOOTNOTES

We acknowledge the support of National Institute of Diabetes and Digestive and Kidney Diseases Grant 2 R37 DK-15350, a grant from the Crohn's and Colitis Foundation of America, and support from The Keating Fund for Research Prevention of Cancer, administered by the University of Texas Medical Branch (UTMB) Small Grants Program, UTMB at Galveston.

Address for reprint requests and other correspondence: D. W. Powell, Dept. of Internal Medicine, Univ. of Texas Medical Branch at Galveston, 4.108 John Sealy Annex 0567, 301 Univ. Blvd., Galveston, TX 77555-0567 (E-mail: dpowell{at}utmb.edu).


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
ROLES IN HEALTH AND...
DEFINITION OF A MYOFIBROBLAST
ORIGIN OF MYOFIBROBLASTS AND...
ACTIVATION, PROLIFERATION, AND...
ROLE IN WOUND REPAIR
ROLE IN FIBROSIS
CONCLUSIONS AND SPECULATION
REFERENCES

1.   Acevedo, C. H., and A. Ahmed. Hemeoxygenase-1 inhibits human myometrial contractility via carbon monoxide and is upregulated by progesterone during pregnancy. J. Clin. Invest. 101: 949-955, 1998[Abstract/Free Full Text].

2.   Aigner, T., D. Neureiter, S. Muller, G. Kuspert, J. Belke, and T. Kirchner. Extracellular matrix composition and gene expression in collagenous colitis. Gastroenterology 113: 136-143, 1997[Medline].

3.   Anand-Apte, B., B. R. Zetter, A. Viswanathan, R. G. Qiu, J. Chen, R. Ruggieri, and M. Symons. Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. J. Biol. Chem. 272: 30688-30692, 1997[Abstract/Free Full Text].

4.   Apte, M. V., P. S. Haber, T. L. Applegate, I. D. Norton, G. W. McCaughan, M. A. Korsten, R. C. Pirola, and J. S. Wilson. Periacinar stellate shaped cells in rat pancreas: identification, isolation and culture. Gut 43: 128-133, 1998[Abstract/Free Full Text].

5.   Arenberg, D. A., M. P. Keane, B. DiGiovine, S. L. Kunkel, S. B. Morris, Y. Y. Xue, M. D. Burdick, M. C. Glass, M. D. Iannettoni, and R. M. Strieter. Epithelial neutrophil-activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 102: 465-472, 1998[Abstract/Free Full Text].

6.   Aspenstrom, P. The Rho GTPases have multiple effects on the actin cytoskeleton. Exp. Cell Res. 246: 20-25, 1999[Medline].

7.   Babyatsky, M. W., M. deBeaumont, L. Thim, and D. K. Podolsky. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 110: 489-497, 1996[Medline].

8.   Bachem, M. G., E. Schneider, H. Gross, H. Weidenbach, R. M. Schmid, A. Menke, M. Siech, H. Beger, A. Grunert, and G. Adler. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115: 421-432, 1998[Medline].

9.   Bahn, R. S. The fibroblast is the target cell in the connective tissue manifestations of Graves' disease. Int. Arch. Allergy Immunol. 106: 213-218, 1998.

10.   Bajaj-Elliott, M., R. Poulsom, S. L. Pender, N. C. Wathen, and T. T. Macdonald. Interactions between stromal cell-derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia. J. Clin. Invest. 102: 1473-1480, 1998[Abstract/Free Full Text].

11.   Baker, D. G., J. Dayer, M. Roelke, H. R. Schumacher, and S. M. Krane. Rheumatoid synovial cell morphologic changes induced by a mononuclear cell factor in culture. Arthritis Rheum. 26: 8-14, 1983[Medline].

12.   Barnard, J. A., R. D. Beauchamp, W. E. Russell, R. N. DuBois, and R. J. Coffey. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 108: 564-580, 1995[Medline].

13.   Barsky, S. H., W. R. Green, G. R. Grotendorst, and L. A. Liotta. Desmoplastic breast carcinoma as a source of human myofibroblasts. Am. J. Pathol. 115: 329-333, 1984[Abstract].

14.   Bauer, I., G. A. Wanner, H. Rensing, C. Alte, E. A. Miescher, B. Wolf, B. H. Pannen, M. G. Clemens, and M. Bauer. Expression pattern of heme oxygenase isoenzymes 1 and 2 in normal and stress-exposed rat liver. Hepatology 27: 829-838, 1998[Medline].

15.   Beecher, K. L., T. T. Andersen, J. W. Fenton, and B. W. Festoff. Thrombin receptor peptides induce shape change in neonatal murine astrocytes in culture. J. Neurosci. Res. 37: 108-115, 1994[Medline].

16.   Benyon, R. C., J. P. Iredale, S. Goddard, P. J. Winwood, and M. J. Arthur. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110: 821-831, 1996[Medline].

17.   Berndt, A., H. Kosmehl, U. Mandel, U. Gabler, X. Luo, D. Celeda, L. Zardi, and D. Katenkamp. TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem. J. 27: 1014-1020, 1995[Medline].

18.   Bernex, F., P. De Sepulveda, C. Kress, C. Elbaz, C. Delouis, and J. J. Panthier. Spatial and temporal patterns of c-kit-expressing cells in WlacZ/+ and WlacZ/WlacZ mouse embryos. Development 122: 3023-3033, 1996[Abstract/Free Full Text].

19.   Berschneider, H. M., and D. W. Powell. Fibroblasts modulate intestinal secretory responses to inflammatory mediators. J. Clin. Invest. 89: 484-489, 1992[Medline].

20.   Birchmeier, C., and W. Birchmeier. Molecular aspects of mesenchymal-epithelial interactions. Annu. Rev. Cell Biol. 9: 511-540, 1993.

21.   Bissell, D. M., and J. J. Maher. Hepatic fibrosis and cirrhosis. In: Hepatology: A Textbook of Liver Disease, edited by D. Zakim, and T. D. Boyer. Philadelphia, PA: Saunders, 1996, p. 506-525.

22.   Bissell, D. M., S. S. Wang, W. R. Jarnagin, and F. J. Roll. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J. Clin. Invest. 96: 447-455, 1995[Medline].

23.   Blikslager, A. T., M. C. Roberts, J. M. Rhoads, and R. A. Argenzio. Prostaglandins I2 and E2 have a synergistic role in rescuing epithelial barrier function in porcine ileum. J. Clin. Invest. 100: 1928-1933, 1997[Abstract/Free Full Text].

24.   Bockman, D. E., and G. S. Sohal. A new source of cells contributing to the developing gastrointestinal tract demonstrated in chick embryos. Gastroenterology 114: 878-882, 1998[Medline].

25.   Border, W. A., and N. A. Noble. Transforming growth factor beta  in tissue fibrosis. N. Engl. J. Med. 331: 1286-1292, 1994[Free Full Text].

26.   Bostrom, H., K. Willetts, M. Pekny, P. Leveen, P. Lindahl, H. Hedstrand, M. Pekna, M. Hellstrom, S. Gebre-Medhin, M. Schalling, M. Nilsson, S. Kurland, J. Tornell, J. K. Heath, and C. Betsholtz. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85: 863-873, 1996[Medline].

27.   Boya, J., A. L. Carbonell, and A. Martinez. Myofibroblasts in human palatal mucosa. Acta Anat. (Basel) 131: 161-165, 1988[Medline].

28.   Bradbury, J. A two-pronged approach to the clinical use of HGF. Lancet 351: 272, 1998[Medline].

29.   Bradham, D. M., A. Igarashi, R. L. Potter, and G. R. Grotendorst. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J. Cell Biol. 114: 1285-1294, 1991[Abstract].

30.   Buniatian, G., B. Hamprecht, and R. Gebhardt. Glial fibrillary acidic protein as a marker of perisinusoidal stellate cells that can distinguish between the normal and myofibroblast-like phenotypes. Biol. Cell 87: 65-73, 1996[Medline].

31.   Burns, A. R., S. I. Simon, G. L. Kukielka, J. L. Rowen, H. Lu, L. H. Mendoza, E. S. Brown, M. L. Entman, and C. W. Smith. Chemotactic factors stimulate CD18-dependent canine neutrophil adherence and motility on lung fibroblasts. J. Immunol. 156: 3389-3401, 1996[Abstract].

32.   Bussey, H. Cell shape determination: a pivotal role for Rho. Science 272: 224-225, 1996[Medline].

33.   Campbell, F., B. Hewlett, J. Ho, J. Huizinga, and R. H. Riddell. Interstitial cells of Cajal (ICC) are absent or deranged in intestinal pseudo-obstruction (Abstract). Lab. Invest. 78: 61A, 1998.

34.   Campbell, S. E., J. S. Janicki, and K. T. Weber. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J. Mol. Cell. Cardiol. 27: 1545-1560, 1995[Medline].

35.   Campbell, S. E., and L. C. Katwa. Angiotensin II stimulated expression of transforming growth factor-beta 1 in cardiac fibroblasts and myofibroblasts. J. Mol. Cell. Cardiol. 29: 1947-1958, 1997[Medline].

36.   Casola, A., A. Kapoor, J. I. Saada, R. Mifflin, D. W. Powell, and S. E. Crowe. Chemokine expression by intestinal myofibroblasts (Abstract). Gastroenterology 112: A944, 1997.

37.   Chedid, M., J. S. Rubin, K. G. Csaky, and S. A. Aaronson. Regulation of keratinocyte growth factor gene expression by interleukin 1. J. Biol. Chem. 269: 10753-10757, 1994[Abstract/Free Full Text].

38.   Chinery, R., and R. J. Coffey. Trefoil peptides: less clandestine in the intestine. Science 274: 204, 1996[Medline].

39.   Christopherson, K. S., and D. S. Bredt. Nitric oxide in excitable tissues: physiological roles and disease. J. Clin. Invest. 100: 2424-2429, 1997[Free Full Text].

40.   Cintorino, M., E. Bellizzi de Marco, P. Leoncini, S. A. Tripodi, L. J. Xu, A. P. Sappino, A. Schmitt-Graff, and G. Gabbiani. Expression of alpha -smooth-muscle actin in stromal cells of the uterine cervix during epithelial neoplastic changes. Int. J. Cancer 47: 843-846, 1991[Medline].

41.   Clark, R. A. Regulation of fibroplasia in cutaneous wound repair. Am. J. Med. Sci. 306: 42-48, 1993[Medline].

42.   Clemmons, D. R. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 8: 45-62, 1997[Medline].

43.   Clemmons, D. R. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol. Cell. Endocrinol. 140: 19-24, 1998[Medline].

44.   Clemmons, D. R., W. Busby, J. B. Clarke, A. Parker, C. Duan, and T. J. Nam. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Endocr. J. 45, Suppl.: S1-S8, 1998[Medline].

45.   Clouthier, D. E., S. A. Comerford, and R. E. Hammer. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta 1 transgenic mice. J. Clin. Invest. 100: 2697-2713, 1997[Abstract/Free Full Text].

46.   Cockerill, G. W., O. Wiebkin, R. Krishnan, S. Huffam, S. Graves, J. R. Gamble, and M. A. Vadas. Characterisation of a myofibroblast-like cell line from an angiosarcoma. Int. J. Oncol. 9: 411-418, 1996.

47.   Cohn, S. M., S. Schloemann, T. Tessner, K. Seibert, and W. F. Stenson. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest. 99: 1367-1379, 1997[Abstract/Free Full Text].

48.   Crowston, J. G., M. Salmon, P. T. Khaw, and A. N. Akbar. T-lymphocyte-fibroblast interactions. Biochem. Soc. Trans. 25: 529-531, 1997[Medline].

49.   Czernobilsky, B., E. Shezen, B. Lifschitz-Mercer, M. Fogel, A. Luzon, N. Jacob, O. Skalli, and G. Gabbiani. Alpha smooth muscle actin (alpha-SM actin) in normal human ovaries, in ovarian stromal hyperplasia and in ovarian neoplasms. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 57: 55-61, 1989[Medline].

50.   D'Amore, P. A. Capillary growth: a two-cell system. Semin. Cancer Biol. 3: 49-56, 1992[Medline].

51.   Darby, I., O. Skalli, and G. Gabbiani. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab. Invest. 63: 21-29, 1990[Medline].

52.   Der-Silaphet, T., J. Malysz, S. Hagel, A. L. Arsenault, and J. D. Huizinga. Interstitial cells of Cajal direct normal propulsive contractile activity in the mouse small intestine. Gastroenterology 114: 724-736, 1998[Medline].

53.   Desaki, J., T. Fujiwara, and T. Komuro. A cellular reticulum of fibroblast-like cells in the rat intestine: scanning and transmission electron microscopy. Arch. Histol. Jpn. 47: 179-186, 1984[Medline].

54.   Desmouliere, A., and G. Gabbiani. Myofibroblast differentiation during fibrosis. Exp. Nephrol. 3: 134-139, 1995[Medline].

55.   Desmouliere, A., M. Redard, I. Darby, and G. Gabbiani. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 146: 56-66, 1995[Abstract].

56.   Desmouliere, A., L. Rubbia-Brandt, A. Abdiu, T. Walz, A. Macieira-Coelho, and G. Gabbiani. Alpha-smooth muscle actin is expressed in a subpopulation of cultured and cloned fibroblasts and is modulated by gamma-interferon. Exp. Cell Res. 201: 64-73, 1992[Medline].

57.   Diehl, A. M., and R. M. Rai. Liver regeneration 3: regulation of signal transduction during liver regeneration. FASEB J. 10: 215-227, 1996[Abstract/Free Full Text].

58.   Dignass, A. U., and D. K. Podolsky. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta . Gastroenterology 105: 1323-1332, 1993[Medline].

59.   Dignass, A. U., S. Tsunekawa, and D. K. Podolsky. Fibroblast growth factors modulate intestinal epithelial cell growth and migration. Gastroenterology 106: 1254-1262, 1994[Medline].

60.   Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147, 1996[Abstract/Free Full Text].

61.   Doucet, C., D. Brouty-Boye, C. Pottin-Clemenceau, G. W. Canonica, C. Jasmin, and B. Azzarone. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J. Clin. Invest. 101: 2129-2139, 1998[Abstract/Free Full Text].

62.   Enzan, H., H. Himeno, S. Iwamura, T. Saibara, S. Onishi, Y. Yamamoto, E. Miyazaki, and H. Hara. Sequential changes in human Ito cells and their relation to postnecrotic liver fibrosis in massive and submassive hepatic necrosis. Virchows Arch. 426: 95-101, 1995[Medline].

63.   Espinoza, L. R., R. van Solingen, M. L. Cuellar, and J. Angulo. Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am. J. Med. Sci. 316: 271-276, 1998[Medline].

64.   Estevao-Costa, J., J. Correia-Pinto, F. C. Rodrigues, J. L. Carvalho, M. Campos, J. A. Dias, F. Carneiro, and N. T. Santos. Gastric inflammatory myofibroblastic proliferation in children. Pediatr. Surg. Int. 13: 95-99, 1998[Medline].

65.   Eyden, B. P. Brief review of the fibronexus and its significance for myofibroblastic differentiation and tumor diagnosis. Ultrastruct. Pathol. 17: 611-622, 1993[Medline].

66.   Finch, P. W., V. Pricolo, A. Wu, and S. D. Finkelstein. Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology 110: 441-451, 1996[Medline].

67.   Fiocchi, C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): G769-G775, 1997[Abstract/Free Full Text].

68.   Flaumenhaft, R., M. Abe, P. Mignatti, and D. B. Rifkin. Basic fibroblast growth factor-induced activation of latent transforming growth factor in endothelial cells: regulation of plasminogen activator activity. J. Cell Biol. 118: 901-909, 1992[Abstract].

69.   Forstermann, U., J. P. Boissel, and H. Kleinert. Expressional control of the "constitutive" isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 12: 773-790, 1998[Abstract/Free Full Text].

70.   Frazier, K. S., and G. R. Grotendorst. Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors. Int. J. Biochem. Cell Biol. 29: 153-161, 1997[Medline].

71.   Friedman, S. L. The cellular basis of hepatic fibrosis. N. Engl. J. Med. 328: 1828-1835, 1993[Free Full Text].

72.   Friedman, S. L. Closing in on the signals of hepatic fibrosis. Gastroenterology 112: 1406-1409, 1997[Medline].

73.   Fries, K. M., T. Blieden, R. J. Looney, G. D. Sempowski, M. R. Silvera, R. A. Willis, and R. P. Phipps. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin. Immunol. Immunopathol. 72: 283-292, 1994[Medline].

74.   Fritsch, C., P. Simon-Assmann, M. Kedinger, and G. S. Evans. Cytokines modulate fibroblast phenotype and epithelial-stroma interactions in rat intestine. Gastroenterology 112: 826-838, 1997[Medline].

75.   Fuchs, E., and D. W. Cleveland. A structural scaffolding of intermediate filaments in health and disease. Science 279: 514-519, 1998[Abstract/Free Full Text].

76.   Fujimoto, J., M. Hori, S. Ichigo, and T. Tamaya. Ovarian steroids regulate the expression of basic fibroblast growth factor and its mRNA in fibroblasts derived from uterine endometrium. Ann. Clin. Biochem. 34: 91-96, 1997[Medline].

77.   Furuya, K., S. Furuya, and S. Yamagishi. Intracellular calcium responses and shape conversions induced by endothelin in cultured subepithelial fibroblasts of rat duodenal villi. Pflügers Arch. 428: 97-104, 1994[Medline].

78.   Furuya, S., and K. Furuya. Characteristics of cultured subepithelial fibroblasts of rat duodenal villi. Anat. Embryol. 187: 529-538, 1993[Medline].

79.   Furuya, S., R. Nagata, Y. Ozaki, K. Furuya, T. Nakayama, and M. Nagahama. A monoclonal antibody to astrocytes, subepithelial fibroblasts of small intestinal villi and interstitial cells of the myenteric plexus layer. Anat. Embryol. 195: 113-126, 1997[Medline].

80.   Furuya, S., S. Naruse, T. Nakayama, and K. Nokihara. 125I-endothelin binds to fibroblasts beneath the epithelium of rat small intestine. J. Electron Microsc. 39: 264-268, 1990[Medline].

81.   Gabbiani, G. The cellular derivation and the life span of the myofibroblast. Pathol. Res. Pract. 192: 708-711, 1996[Medline].

82.   Gabbiani, G., and E. Rungger-Brandle. The fibroblast. In: Handbook of Inflammation. Tissue Repair and Regeneration, edited by L. E. Glynn. Amsterdam: Elsevier/North-Holland Biomedical, 1981, p. 1-50.

83.   Gabbiani, G., G. B. Ryan, and G. Majne. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 27: 549-550, 1971[Medline].

84.   Goke, M., M. Kanai, and D. K. Podolsky. Intestinal fibroblasts regulate intestinal epithelial cell proliferation via hepatocyte growth factor. Am. J. Physiol. 274 (Gastrointest. Liver Physiol. 37): G809-G818, 1998[Abstract/Free Full Text].

85.   Gorgas, K., and P. Bock. Myofibroblasts in the rat testicular capsule. Cell Tissue Res. 154: 533-541, 1974[Medline].

86.   Graham, M. F. Pathogenesis of intestinal strictures in Crohn's disease---an update. Inflamm. Bowel Dis. 1: 220-227, 1995.

87.   Greenhalgh, D. G., K. H. Sprugel, M. J. Murray, and R. Ross. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am. J. Pathol. 136: 1235-1246, 1990[Abstract].

88.   Gressner, A. M. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int. Suppl. 54: S39-S45, 1996[Medline].

89.   Grotendorst, G. R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8: 171-179, 1997[Medline].

90.   Guido, M., M. Rugge, L. Chemello, G. Leandro, G. Fattovich, G. Giustina, M. Cassaro, and A. Alberti. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J. Hepatol. 24: 301-307, 1996[Medline].

91.   Gulati, R., and J. J. Peluso. Opposing actions of hepatocyte growth factor and basic fibroblast growth factor on cell contact, intracellular free calcium levels, and rat ovarian surface epithelial cell viability. Endocrinology 138: 1847-1856, 1997[Abstract/Free Full Text].

92.   Gurbuz, A. K., F. M. Giardiello, G. M. Petersen, A. J. Krush, G. J. Offerhaus, S. V. Booker, M. C. Kerr, and S. R. Hamilton. Desmoid tumours in familial adenomatous polyposis. Gut 35: 377-381, 1994[Abstract].

93.   Gurner, A. The origin of Ia antigen-expressing cells in the rat kidney. Am. J. Pathol. 127: 342-348, 1987[Abstract].

94.   Hall, A. Rho GTPases and the actin cytoskeleton. Science 279: 509-514, 1998[Abstract/Free Full Text].

95.   Hall, P. A., P. J. Coates, B. Ansari, and D. Hopwood. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J. Cell Sci. 107: 3569-3577, 1994[Abstract/Free Full Text].

96.   Hanauske-Abel, H. M. Fibrosis: representative molecular elements, a basic concept, and emerging targets for suppressive treatment. In: Hepatology: A Textbook of Liver Disease, edited by D. Zakim, and T. D. Boyer. Philadelphia, PA: Saunders, 1996, p. 465-506.

97.   Hautmann, M. B., C. S. Madsen, and G. K. Owens. A transforming growth factor beta  (TGFbeta ) control element drives TGFbeta -induced stimulation of smooth muscle alpha -actin gene expression in concert with two CArG elements. J. Biol. Chem. 272: 10948-10956, 1997[Abstract/Free Full Text].

98.   Hayward, S. W., M. A. Rosen, and G. R. Cunha. Stromal-epithelial interactions in the normal and neoplastic prostate. Br. J. Urol. 79, Suppl. 2: 18-26, 1997[Medline].

99.   Hebda, P. A., M. A. Collins, and M. D. Tharp. Mast cell and myofibroblast in wound healing. Dermatol. Clin. 11: 685-696, 1993[Medline].

100.   Hellerbrand, S., C. Wang, H. Tsukamoto, D. A. Brenner, and R. A. Rippe. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 24: 670-676, 1996[Medline].

101.   Hernandez-Munoz, I., P. de la Torre, J. A. Sanchez-Alcazar, I. Garcia, E. Santiago, M. T. Munoz-Yague, and J. A. Solis-Herruzo. Tumor necrosis factor alpha  inhibits collagen alpha  1(I) gene expression in rat hepatic stellate cells through a G protein. Gastroenterology 113: 625-640, 1997[Medline].

102.   Hinterleitner, T. A., J. I. Saada, H. M. Berschneider, D. W. Powell, and J. D. Valentich. IL-1 stimulates intestinal myofibroblast COX gene expression and augments activation of Cl- secretion in T84 cells. Am. J. Physiol. 271 (Cell Physiol. 40): C1262-C1268, 1996[Abstract/Free Full Text].

103.   Hirota, S., K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, K. Kawano, M. Hanada, A. Kurata, M. Takeda, T. G. Muhammad, Y. Matsuzawa, Y. Kanakura, Y. Shinomura, and Y. Kitamura. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998[Abstract/Free Full Text].

104.   Hoeben, E., T. Briers, H. Vanderstichele, W. De Smet, W. Heyns, L. Deboel, F. Vanderhoydonck, and G. Verhoeven. Characterization of newly established testicular peritubular and prostatic stromal cell lines: potential use in the study of mesenchymal-epithelial interactions. Endocrinology 136: 2862-2873, 1995[Abstract].

105.   Hogaboam, C. M., R. E. Smith, and S. L. Kunkel. Dynamic interactions between lung fibroblasts and leukocytes: implications for fibrotic lung disease. Proc. Assoc. Am. Physicians 110: 313-320, 1998[Medline].

106.   Holstein, A. F., M. Maekawa, T. Nagano, and M. S. Davidoff. Myofibroblasts in the lamina propria of human seminiferous tubules are dynamic structures of heterogeneous phenotype. Arch. Histol. Cytol. 59: 109-125, 1996[Medline].

107.   Housley, R. M., C. F. Morris, W. Boyle, B. Ring, R. Biltz, J. E. Tarpley, S. L. Aukerman, P. L. Devine, R. H. Whitehead, and G. F. Pierce. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J. Clin. Invest. 94: 1764-1777, 1994[Medline].

108.   Hricik, D. E., M. Chung-Park, and J. R. Sedor. Glomerulonephritis. N. Engl. J. Med. 339: 888-899, 1998[Free Full Text].

109.   Huizinga, J. D., L. Thuneberg, M. Kluppel, J. Malysz, H. B. Mikkelsen, and A. Bernstein. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373: 347-349, 1995[Medline].

110.   Hull, M. A., D. J. Cullen, N. Hudson, and C. J. Hawkey. Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration. Gut 37: 610-612, 1995[Abstract].

111.   Ichiki, Y., E. Smith, E. C. LeRoy, and M. Trojanowska. Different effects of basic fibroblast growth factor and transforming growth factor-beta on the two platelet-derived growth factor receptors' expression in scleroderma and healthy human dermal fibroblasts. J. Invest. Dermatol. 104: 124-127, 1995[Abstract].

112.   Igarashi, A., H. Okochi, D. M. Bradham, and G. R. Grotendorst. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell 4: 637-645, 1993[Abstract].

113.   Iredale, J. P., R. C. Benyon, J. Pickering, M. McCullen, M. Northrop, S. Pawley, C. Hovell, and M. J. Arthur. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 102: 538-549, 1998[Abstract/Free Full Text].

114.   Isaji, M., Y. Momose, Y. Tatsuzawa, and J. Naito. Modulation of morphology, proliferation and collagen synthesis in fibroblasts by the exudate from hypersensitive granulomatous inflammation in rats. Int. Arch. Allergy Immunol. 104: 340-347, 1994[Medline].

115.   Isozaki, K., S. Hirota, J. Miyagawa, M. Taniguchi, Y. Shinomura, and Y. Matsuzawa. Deficiency of c-kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo-obstruction. Am. J. Gastroenterol. 92: 332-334, 1997[Medline].

116.   Iwasaki, H., T. Isayama, T. Ichiki, and M. Kikuchi. Intermediate filaments of myofibroblasts. Immunochemical and immunocytochemical analyses. Pathol. Res. Pract. 182: 248-254, 1987[Medline].

117.   Jain, M. K., M. D. Layne, M. Watanabe, M. T. Chin, M. W. Feinberg, N. E. Sibinga, C. M. Hsieh, S. F. Yet, D. L. Stemple, and M. E. Lee. In vitro system for differentiating pluripotent neural crest cells into smooth muscle cells. J. Biol. Chem. 273: 5993-5996, 1998[Abstract/Free Full Text].

118.   Jarnagin, W. R., D. C. Rockey, V. E. Koteliansky, S. S. Wang, and D. M. Bissell. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J. Cell Biol. 127: 2037-2048, 1994[Abstract].

119.   Jobson, T. M., C. K. Billington, and I. P. Hall. Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation. J. Clin. Invest. 101: 2650-2657, 1998[Abstract/Free Full Text].

120.   Joyce, N. C., M. F. Haire, and G. E. Palade. Morphologic and biochemical evidence for a contractile cell network within the rat intestinal mucosa. Gastroenterology 92: 68-81, 1987[Medline].

121.   Kaiser, G. C., and D. B. Polk. Tumor necrosis factor alpha  regulates proliferation in a mouse intestinal cell line. Gastroenterology 112: 1231-1240, 1997[Medline].

122.   Kaneda, K., W. Ekataksin, M. Sogawa, A. Matsumura, A. Cho, and N. Kawada. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 27: 735-747, 1998[Medline].

123.   Kapanci, Y., S. Burgan, G. G. Pietra, B. Conne, and G. Gabbiani. Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension. Am. J. Pathol. 136: 881-889, 1990[Abstract].

124.   Kasper, M., F. Golfert, and R. H. Funk. Immunoelectron microscopical characterization of the epithelioid type of smooth muscle cells in human glomus organs. Ultrastruct. Pathol. 21: 425-430, 1997[Medline].

125.   Kassen, A., D. M. Sutkowski, H. Ahn, J. A. Sensibar, J. M. Kozlowski, and C. Lee. Stromal cells of the human prostate: initial isolation and characterization. Prostate 28: 89-97, 1996[Medline].

126.   Kaye, G. I., R. R. Pascal, and N. Lane. The colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue. 3. Replication and differentiation in human hyperplastic and adenomatous polyps. Gastroenterology 60: 515-536, 1971[Medline].

127.   Keane, M. P., D. A. Arenberg, B. B. Moore, C. L. Addison, and R. M. Strieter. CXC chemokines and angiogenesis/angiostasis. Proc. Assoc. Am. Physicians 110: 288-296, 1998[Medline].

128.   Keegan, A. D., J. J. Ryan, and W. E. Paul. IL-4 regulates growth and differentiation by distinct mechanisms. Immunologist 4: 194-198, 1996.

129.   Khulusi, S., A. M. Hanby, J. M. Marrero, P. Patel, M. A. Mendall, S. Badve, R. Poulsom, G. Elia, N. A. Wright, and T. C. Northfield. Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers. Gut 37: 205-209, 1995[Abstract].

130.   Kindon, H., C. Pothoulakis, L. Thim, K. Lynch-Devaney, and D. K. Podolsky. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 109: 516-523, 1995[Medline].

131.   Kinzler, K. W., and B. Vogelstein. Landscaping the cancer terrain. Science 280: 1036-1037, 1998[Free Full Text].

132.   Klimpel, G. R., K. E. Langley, J. Wypych, J. S. Abrams, A. K. Chopra, and D. W. Niesel. A role for stem cell factor (SCF): c-kit interaction(s) in the intestinal tract response to Salmonella typhimurium infection. J. Exp. Med. 184: 271-276, 1996[Abstract].

133.   Knittel, T., S. Aurisch, K. Neubauer, S. Eichhorst, and G. Ramadori. Cell-type-specific expression of neural cell adhesion molecule (N-CAM) in Ito cells of rat liver. Up-regulation during in vitro activation and in hepatic tissue repair. Am. J. Pathol. 149: 449-462, 1996[Abstract].

134.   Kohnen, G., S. Kertschanska, R. Demir, and P. Kaufmann. Placental villous stroma as a model system for myofibroblast differentiation. Histochem. Cell Biol. 105: 415-429, 1996[Medline].

135.   Kolm-Litty, V., U. Sauer, A. Nerlich, R. Lehmann, and E. D. Schleicher. High glucose-induced transforming growth factor beta 1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101: 160-169, 1998[Abstract/Free Full Text].

136.   Komuro, T. Re-evaluation of fibroblasts and fibroblast-like cells. Anat. Embryol. 182: 103-112, 1990[Medline].

137.   Kothapalli, D., N. Hayashi, and G. R. Grotendorst. Inhibition of TGF-beta -stimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle. FASEB J. 12: 1151-1161, 1998[Abstract/Free Full Text].

138.   Kovacs, E. J., and L. A. DiPietro. Fibrogenic cytokines and connective tissue production. FASEB J. 8: 854-861, 1994[Abstract/Free Full Text].

139.   Kwon, B. S., S. Wang, N. Udagawa, V. Haridas, Z. H. Lee, K. K. Kim, K. O. Oh, J. Greene, Y. Li, J. Su, R. Gentz, B. B. Aggarwal, and J. Ni. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 12: 845-854, 1998[Abstract/Free Full Text].

140.   Lefebvre, O., M. P. Chenard, R. Masson, J. Linares, A. Dierich, M. LeMeur, C. Wendling, C. Tomasetto, P. Chambon, and M. C. Rio. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274: 259-262, 1996[Abstract/Free Full Text].

141.   Leveen, P., M. Pekny, S. Gebre-Medhin, B. Swolin, E. Larsson, and C. Betsholtz. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 8: 1875-1887, 1994[Abstract].

142.   Lindahl, P., B. R. Johansson, P. Leveen, and C. Betsholtz. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245, 1997[Abstract/Free Full Text].

143.   Liu, Q., X. X. Du, D. T. Schindel, Z. X. Yang, F. J. Rescorla, D. A. Williams, and J. L. Grosfeld. Trophic effects of interleukin-11 in rats with experimental short bowel syndrome. J. Pediatr. Surg. 31: 1047-1050, 1996[Medline].

144.   Lund, P. K. Insulin-like growth factors. In: Gut Peptides: Biochemistry and Physiology, edited by G. Dockray, and J. H. Walsh. New York: Raven, 1994, p. 587-613.

145.   Lund, P. K., and E. M. Zimmermann. Insulin-like growth factors and inflammatory bowel disease. In: Cytokines and Growth Factors in Gastroenterology, edited by R. Goodlad, and N. Wright. London: Ballière, Tindal, & Cox, 1996, p. 83-96.

146.   Macdonald, T. T., and S. L. Pender. Proteolytic enzymes in inflammatory bowel disease. Inflamm. Bowel Dis. 4: 157-164, 1998[Medline].

147.   Mallat, A., C. Gallois, J. Tao, A. Habib, J. Maclouf, P. Mavier, A. M. Preaux, and S. Lotersztajn. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J. Biol. Chem. 273: 27300-27305, 1998[Abstract/Free Full Text].

148.   Mallat, A., A. M. Preaux, C. Serradeil-Le Gal, D. Raufaste, C. Gallois, D. A. Brenner, C. Bradham, J. Maclouf, V. Iourgenko, L. Fouassier, D. Dhumeaux, P. Mavier, and S. Lotersztajn. Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway. Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors. J. Clin. Invest. 98: 2771-2778, 1996[Abstract/Free Full Text].

149.   Markowitz, S. D. Atherosclerosis, just another cancer? J. Clin. Invest. 100: 2143-2145, 1997[Free Full Text].

150.   Marra, F., A. Gentilini, M. Pinzani, G. G. Choudhury, M. Parola, H. Herbst, M. U. Dianzani, G. Laffi, H. E. Abboud, and P. Gentilini. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology 112: 1297-1306, 1997[Medline].

151.   Marra, F., G. Grandaliano, A. J. Valente, and H. E. Abboud. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 22: 780-787, 1995[Medline].

152.   Marsh, M. N., and J. S. Trier. Morphology and cell proliferation of subepithelial fibroblasts in adult mouse jejunum. II. Radioautographic studies. Gastroenterology 67: 636-645, 1974[Medline].

153.   Martin, M., P. Pujuguet, and F. Martin. Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Pathol. Res. Pract. 192: 712-717, 1996[Medline].

154.   Martinez-Hernandez, A., and P. S. Amenta. The extracellular matrix in hepatic regeneration. FASEB J. 9: 1401-1410, 1995[Abstract/Free Full Text].

155.   Masur, S. K., H. S. Dewal, T. T. Dinh, I. Erenburg, and S. Petridou. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc. Natl. Acad. Sci. USA 93: 4219-4223, 1996[Abstract/Free Full Text].

156.   Mattey, D. L. Interleukin-4 induces myofibroblast differentiation in synovial fibroblasts. Biochem. Soc. Trans. 25: 290S, 1997[Medline].

157.   Mayer-Proschel, M., M. S. Rao, and M. Noble. Progenitor cells of the central nervous system: a boon for clinical neuroscience. J. NIH Res. 9: 31-36, 1997.

158.   McCafferty, D. M., J. S. Mudgett, M. G. Swain, and P. Kubes. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 112: 1022-1027, 1997[Medline].

159.   McCaffrey, T. A., B. Du, S. Consigli, P. Szabo, P. J. Bray, L. Hartner, B. B. Weksler, T. A. Sanborn, G. Bergman, and H. L. J. Bush. Genomic instability in the type II TGF-beta 1 receptor gene in atherosclerotic and restenotic vascular cells. J. Clin. Invest. 100: 2182-2188, 1997[Abstract/Free Full Text].

160.   Mené, P., M. S. Simonson, and M. J. Dunn. Eicosanoids, mesangial contraction, and intracellular signal transduction. Tohoku J. Exp. Med. 166: 57-73, 1992[Medline].

161.   Mermall, V., P. L. Post, and M. S. Mooseker. Unconventional myosins in cell movement, membrane traffic, and signal transduction. Science 279: 527-533, 1998[Abstract/Free Full Text].

162.   Miller, S. M., G. Farrugia, P. F. Schmalz, L. G. Ermilov, M. D. Maines, and J. H. Szurszewski. Heme oxygenase 2 is present in interstitial cell networks of the mouse small intestine. Gastroenterology 114: 239-244, 1998[Medline].

163.   Moore, R., S. Carlson, and J. L. Madara. Villus contraction aids repair of intestinal epithelium after injury. Am. J. Physiol. 257 (Gastrointest. Liver Physiol. 20): G274-G283, 1989[Abstract/Free Full Text].

164.   Mori, N., Y. Doi, K. Hara, M. Yoshizuka, K. Ohsato, and S. Fujimoto. Role of multipotent fibroblasts in the healing colonic mucosa of rabbits. Ultrastructural and immunocytochemical study. Histol. Histopathol. 7: 583-590, 1992[Medline].

165.   Muchaneta-Kubara, E. C., and A. M. el Nahas. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol. Dial. Transplant. 12: 904-915, 1997[Abstract].

166.   Mucke, L., and M. Eddleston. Astrocytes in infectious and immune-mediated diseases of the central nervous system. FASEB J. 7: 1226-1232, 1993[Abstract/Free Full Text].

167.   Muhl, H., and J. Pfeilschifter. Amplification of nitric oxide synthase expression by nitric oxide in interleukin 1beta -stimulated rat mesangial cells. J. Clin. Invest. 95: 1941-1946, 1995[Medline].

168.   Musso, O., M. Rehn, J. Saarela, N. Theret, J. Lietard, Hintikka, D. Lotrian, J. P. Campion, T. Pihlajaniemi, and B. Clement. Collagen XVIII is localized in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver. Hepatology 28: 98-107, 1998[Medline].

169.   Nakamura, M., and H. Ishii. Myofibroblasts and ECL cells are altered in the aged rat stomach (Abstract). Gastroenterology 114: A240, 1998.

170.   Nakamura, M., M. Oda, Y. Nishizaki, K. Kaneko, T. Azuma, and M. Tsuchiya. Fluorescent histochemical study on the localization of myofibroblasts in the healing of acetic acid-induced gastric ulcers in the rat. Scand. J. Gastroenterol. Suppl. 162: 150-153, 1989[Medline].

171.   Ng, Y. Y., T. P. Huang, W. C. Yang, Z. P. Chen, A. H. Yang, W. Mu, D. J. Nikolic-Paterson, R. C. Atkins, and H. Y. Lan. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 54: 864-876, 1998[Medline].

172.   Novotny, G. E., and H. Pau. Myofibroblast-like cells in human anterior capsular cataract. Virchows Arch. A Pathol. Anat. Histopathol. 404: 393-401, 1984[Medline].

173.   Nusrat, A., C. A. Parkos, A. E. Bacarra, P. J. Godowski, C. Delp-Archer, E. M. Rosen, and J. L. Madara. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J. Clin. Invest. 93: 2056-2065, 1994[Medline].

174.   Ogawa, M., Y. Matsuzaki, S. Nishikawa, S. Hayashi, T. Kunisada, T. Sudo, T. Kina, and H. Nakauchi. Expression and function of c-kit in hemopoietic progenitor cells. J. Exp. Med. 174: 63-71, 1991[Abstract].

175.   Orazi, A., X. Du, Z. Yang, M. Kashai, and D. A. Williams. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab. Invest. 75: 33-42, 1996[Medline].

176.   Pache, J. C., P. G. Christakos, D. E. Gannon, J. J. Mitchell, R. B. Low, and K. O. Leslie. Myofibroblasts in diffuse alveolar damage of the lung. Mod. Pathol. 11: 1064-1070, 1998[Medline].

177.   Palmer, B. F. The renal tubule in the progression of chronic renal failure. J. Investig. Med. 45: 346-361, 1997[Medline].

178.   Pang, G., L. Couch, R. Batey, R. Clancy, and A. Cripps. GM-CSF, IL-1alpha , IL-1beta , IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1alpha and TNFalpha . Clin. Exp. Immunol. 96: 437-443, 1994[Medline].

179.   Papanicolaou, D. A., R. L. Wilder, S. C. Manolagas, and G. P. Chrousos. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128: 127-137, 1998[Abstract/Free Full Text].

180.   Pascal, R. R., G. I. Kaye, and N. Lane. Colonic pericryptal fibroblast sheath: replication, migration, and cytodifferentiation of a mesenchymal cell system in adult tissue. I. Autoradiographic studies of normal rabbit colon. Gastroenterology 54: 835-851, 1968[Medline].

181.   Peehl, D. M., and R. G. Sellers. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp. Cell Res. 232: 208-215, 1997[Medline].

182.   Peled, A., D. Zipori, O. Abramsky, H. Ovadia, and E. Shezen. Expression of alpha -smooth muscle actin in murine bone marrow stromal cells. Blood 78: 304-309, 1991[Abstract].

183.   Pelet, A., O. Geneste, P. Edery, A. Pasini, S. Chappuis, T. Atti, A. Munnich, G. Lenoir, S. Lyonnet, and M. Billaud. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J. Clin. Invest. 101: 1415-1423, 1998[Abstract/Free Full Text].

184.   Petridou, S., and S. K. Masur. Immunodetection of connexins and cadherins in corneal fibroblasts and myofibroblasts. Invest. Ophthalmol. Vis. Sci. 37: 1740-1748, 1996[Abstract].

185.   Pfeilschifter, J. Mesangial cells orchestrate inflammation in the renal glomerulus. News Physiol. Sci. 9: 271-276, 1994.[Abstract/Free Full Text]

186.   Plaut, A. G. Trefoil peptides in the defense of the gastrointestinal tract. N. Engl. J. Med. 336: 506-507, 1997[Free Full Text].

187.   Playford, R. J. Peptides and gastrointestinal mucosal integrity. Gut 37: 595-597, 1995[Medline].

188.   Playford, R. J., and N. A. Wright. Why is epidermal growth factor present in the gut lumen? Gut 38: 303-305, 1996[Abstract].

189.   Podolsky, D. K. Healing the epithelium: solving the problem from two sides. J. Gastroenterol. 32: 122-126, 1997[Medline].

190.   Polk, D. B. Epidermal growth factor receptor-stimulated intestinal epithelial cell migration requires phospholipase C activity. Gastroenterology 114: 493-502, 1998[Medline].

191.  Powell, D. W., R. C. Mifflin, J. D. Valentich, S. E. Crowe, J. I. Saada, and A. B. West. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am. J. Physiol. 277 (Cell Physiol. 46). In press.

192.   Racine-Samson, L., D. C. Rockey, and D. M. Bissell. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J. Biol. Chem. 272: 30911-30917, 1997[Abstract/Free Full Text].

193.   Ramakers, G. J. A., and W. H. Moolenaar. Regulation of astrocyte morphology by RhoA and lysophosphatidic acid. Exp. Cell Res. 245: 252-262, 1998[Medline].

194.   Ray, P., W. Tang, P. Wang, R. Homer, C. Kuhn, R. A. Flavell, and J. A. Elias. Regulated overexpression of interleukin 11 in the lung. Use to dissociate development-dependent and -independent phenotypes. J. Clin. Invest. 100: 2501-2511, 1997[Abstract/Free Full Text].

195.   Reddy, L., H. S. Wang, C. R. Keese, I. Giaever, and T. J. Smith. Assessment of rapid morphological changes associated with elevated cAMP levels in human orbital fibroblasts. Exp. Cell Res. 245: 360-367, 1998[Medline].

196.   Reinecker, H. C., R. P. MacDermott, S. Mirau, A. Dignass, and D. K. Podolsky. Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology 111: 1706-1713, 1996[Medline].

197.   Reitamo, S., A. Remitz, K. Tamai, and J. Uitto. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J. Clin. Invest. 6: 2489-2492, 1994.

198.   Remuzzi, G., and T. Bertani. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 339: 1448-1456, 1998[Free Full Text].

199.   Richman, P. I., R. Tilly, J. R. Jass, and W. F. Bodmer. Colonic pericrypt sheath cells: characterisation of cell type with new monoclonal antibody. J. Clin. Pathol. 40: 593-600, 1987[Abstract].

200.   Riegler, M., R. Sedivy, T. Sogukoglu, E. Cosentini, G. Bischof, B. Teleky, W. Feil, R. Schiessel, G. Hamilton, and E. Wenzl. Epidermal growth factor promotes rapid response to epithelial injury in rabbit duodenum in vitro. Gastroenterology 111: 28-36, 1996[Medline].

201.   Roberts, A. I., S. C. Nadler, and E. C. Ebert. Mesenchymal cells stimulate human intestinal intraepithelial lymphocytes. Gastroenterology 113: 144-150, 1997[Medline].

202.   Rockey, D. C., and J. J. Chung. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J. Clin. Invest. 95: 1199-1206, 1995[Medline].

203.   Ronnov-Jessen, L., and O. W. Petersen. Induction of alpha -smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 68: 696-707, 1993[Medline].

204.   Ronnov-Jessen, L., O. W. Petersen, V. E. Koteliansky, and M. J. Bissell. The origin of the myofibroblasts in breast cancer: recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Invest. 95: 859-873, 1995[Medline].

205.   Rosenbaum, J., S. Blazejewski, A. M. Preaux, A. Mallat, D. Dhumeaux, and P. Mavier. Fibroblast growth factor 2 and transforming growth factor beta 1 interactions in human liver myofibroblasts. Gastroenterology 109: 1986-1996, 1995[Medline].

206.   Rubbia-Brandt, L., G. Mentha, A. Desmouliere, A. M. Alto Costa, E. Giostra, G. Molas, H. Enzan, and G. Gabbiani. Hepatic stellate cells reversibly express alpha -smooth muscle actin during acute hepatic ischemia. Transplant. Proc. 29: 2390-2395, 1997[Medline].

207.   Rubin, J. S., D. P. Bottaro, M. Chedid, T. Miki, D. Ron, G. Cheon, W. G. Taylor, E. Fortney, H. Sakata, and P. W. Finch. Keratinocyte growth factor. Cell Biol. Int. 19: 399-411, 1995[Medline].

208.   Rungger-Brandle, E., and G. Gabbiani. The role of cytoskeletal and cytocontractile elements in pathologic processes. Top. Clin. Nurs. 8: 361-392, 1986.

209.   Ryu, J. H., T. V. Colby, and T. E. Hartman. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin. Proc. 73: 1085-1101, 1998[Medline].

210.   Saada, J. I., R. Mifflin, and D. W. Powell. Nonsteroidal anti-inflammatory drugs (NSAIDs) induce cyclooxygenase-2 (COX-2) expression via delayed activation of ERK and P38 MAPK pathways in human intestinal subepithelial myofibroblasts synergistic interaction with interleukin-1 induced signaling (Abstract). Gastroenterology 116: A297, 1999.

211.   Salmon-Ehr, V., H. Serpier, B. Nawrocki, P. Gillery, C. Clavel, B. Kalis, P. Birembaut, and F. X. Maquart. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch. Dermatol. 132: 802-806, 1996[Abstract].

212.   Sanders, K. M. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 111: 492-515, 1996[Medline].

213.   Sappino, A. P., I. Masouye, J. H. Saurat, and G. Gabbiani. Smooth muscle differentiation in scleroderma fibroblastic cells. Am. J. Pathol. 137: 585-591, 1990[Abstract].

214.   Sappino, A. P., W. Schurch, and G. Gabbiani. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab. Invest. 63: 144-161, 1990[Medline].

215.   Saunders, K. B., and P. A. D'Amore. An in vitro model for cell-cell interactions. In Vitro Cell. Dev. Biol. 28A: 521-528, 1992.

216.   Schmitt-Graff, A., A. Desmouliere, and G. Gabbiani. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch. 425: 3-24, 1994[Medline].

217.   Schmitt-Graff, A., H. Pau, R. Spahr, H. M. Piper, O. Skalli, and G. Gabbiani. Appearance of alpha -smooth muscle actin in human eye lens cells of anterior capsular cataract and in cultured bovine lens-forming cells. Differentiation 43: 115-122, 1990[Medline].

218.   Schmitt-Graff, A., O. Skalli, and G. Gabbiani. Alpha-smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 57: 291-302, 1989[Medline].

219.   Schuppan, D., M. Schmid, R. Somasundaram, R. Ackermann, M. Ruehl, T. Nakamura, and E. O. Riecken. Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology 114: 139-152, 1998[Medline].

220.   Scott-Burden, T. Extracellular matrix: the cellular environment. News Physiol. Sci. 9: 110-115, 1994.[Abstract/Free Full Text]

221.   Sempowski, G. D., J. Rozenblit, T. J. Smith, and R. P. Phipps. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am. J. Physiol. 274 (Cell Physiol. 43): C707-C714, 1998[Abstract/Free Full Text].

222.   Serini, G., M. L. Bochaton-Piallat, P. Ropraz, A. Geinoz, L. Borsi, L. Zardi, and G. Gabbiani. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta 1. J. Cell Biol. 142: 873-881, 1998[Abstract/Free Full Text].

223.   Shi, Y., J. E. O'Brien, Jr., A. Fard, and A. Zalewski. Transforming growth factor-beta 1 expression and myofibroblast formation during arterial repair. Arterioscler. Thromb. Vasc. Biol. 16: 1298-1305, 1996[Abstract/Free Full Text].

224.   Shum, D. T., and R. M. McFarlane. Histogenesis of Dupuytren's disease: an immunohistochemical study of 30 cases. J. Hand Surg. [Am.] 13: 61-67, 1988[Medline].

225.   Silen, W., and S. Ito. Mechanisms for rapid re-epithelialization of the gastric mucosal surface. Annu. Rev. Physiol. 47: 217-229, 1985[Medline].

226.   Simmons, J. G., J. B. Pucilowska, and P. K. Lund. Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors. Am. J. Physiol. 276 (Gastrointest. Liver Physiol. 39): G817-G827, 1999[Abstract/Free Full Text].

227.   Simon-Assmann, P., M. Kedinger, A. De Arcangelis, V. Rousseau, and P. Simo. Extracellular matrix components in intestinal development. Experientia 51: 883-900, 1995[Medline].

228.   Singer, I. I. The fibronexus: a transmembrane association of fibronectin-containing fibers and bundles of 5 nm microfilaments in hamster and human fibroblasts. Cell 16: 675-685, 1979[Medline].

229.   Singer, I. I. Fibronexus formation is an early event during fibronectin-induced restoration of more normal morphology and substrate adhesion patterns in transformed hamster fibroblasts. J. Cell Sci. 56: 1-20, 1982[Abstract].

230.   Singer, I. I., D. M. Kazazis, and D. W. Kawka. Localization of the fibronexus at the surface of granulation tissue myofibroblasts using double-label immunogold electron microscopy on ultrathin frozen sections. Eur. J. Cell Biol. 38: 94-101, 1985[Medline].

231.   Singer, I. I., D. M. Kazazis, D. W. Kawka, E. A. Rupp, and E. K. Bayne. Extracellular matrix-cytoskeletal interactions in rheumatoid arthritis. I. Immunoelectron microscopic analysis of the fibronexus at the adhesive surface of normal porcine type B synoviocytes in vitro. Arthritis Rheum. 28: 1105-1116, 1985[Medline].

232.   Singer, I. I., and P. R. Paradiso. A transmembrane relationship between fibronectin and vinculin (130 kd protein): serum modulation in normal and transformed hamster fibroblasts. Cell 24: 481-492, 1981[Medline].

233.   Smits, R., W. van der Houven van Oordt, A. Luz, C. Zurcher, S. Jagmohan-Changur, C. Breukel, P. M. Khan, and R. Fodde. Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology 114: 275-283, 1998[Medline].

234.   Soriano, P. Abnormal kidney development and hematological disorders in PDGF beta -receptor mutant mice. Genes Dev. 8: 1888-1896, 1994[Abstract].

235.   Sprenger, H., A. Kaufmann, H. Garn, B. Lahme, D. Gemsa, and A. M. Gressner. Induction of neutrophil-attracting chemokines in transforming rat hepatic stellate cells. Gastroenterology 113: 277-285, 1997[Medline].

236.   Strong, S. A., T. T. Pizarro, J. S. Klein, F. Cominelli, and C. Fiocchi. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology 114: 1244-1256, 1998[Medline].

237.   Synnerstad, I., E. Ekblad, F. Sundler, and L. Holm. Gastric mucosal smooth muscles may explain oscillations in glandular pressure: role of vasoactive intestinal peptide. Gastroenterology 114: 284-294, 1998[Medline].

238.   Tamm, E. R., A. Siegner, A. Baur, and E. Lutjen-Drecoll. Transforming growth factor-beta 1 induces alpha -smooth muscle-actin expression in cultured human and monkey trabecular meshwork. Exp. Eye Res. 62: 389-397, 1996[Medline].

239.   Tang, W. W., T. R. Ulich, D. L. Lacey, D. C. Hill, M. Qi, S. A. Kaufman, G. Y. Van, J. E. Tarpley, and J. S. Yee. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am. J. Pathol. 148: 1169-1180, 1996[Abstract].

240.   Tetsuka, T., L. D. Baier, and A. R. Morrison. Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells. Evidence for post-transcriptional regulation. J. Biol. Chem. 271: 11689-11693, 1996[Abstract/Free Full Text].

241.   Tetsuka, T., D. Daphna-Iken, S. K. Srivastava, L. D. Baier, J. DuMaine, and A. R. Morrison. Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1. Proc. Natl. Acad. Sci. USA 91: 12168-12172, 1994[Abstract/Free Full Text].

242.   Tomasek, J. J., C. J. Haaksma, R. J. Eddy, and M. B. Vaughan. Fibroblast contraction occurs on release of tension in attached collagen lattices: dependency on an organized actin cytoskeleton and serum. Anat. Rec. 232: 359-368, 1992[Medline].

243.   Torihashi, S., W. T. Gerthoffer, S. Kobayashi, and K. M. Sanders. Identification and classification of interstitial cells in the canine proximal colon by ultrastructure and immunocytochemistry. Histochemistry 101: 169-183, 1994[Medline].

244.   Torihashi, S., S. M. Ward, and K. M. Sanders. Development of c-Kit-positive cells and the onset of electrical rhythmicity in murine small intestine. Gastroenterology 112: 144-155, 1997[Medline].

245.   Uribe, J. M., and K. E. Barrett. Nonmitogenic actions of growth factors: an integrated view of their role in intestinal physiology and pathophysiology. Gastroenterology 112: 255-268, 1997[Medline].

246.   Valentich, J. D., V. Popov, J. I. Saada, and D. W. Powell. Phenotypic characterization of an intestinal subepithelial myofibroblast cell line. Am. J. Physiol. 272 (Cell Physiol. 41): C1513-C1524, 1997[Abstract/Free Full Text].

247.   Valentich, J. D., and D. W. Powell. Intestinal subepithelial myofibroblasts and mucosal immunophysiology. Curr. Opin. Gastroenterol. 10: 645-651, 1994.

248.   Vanderwinden, J. M., H. Liu, M. H. De Laet, and J. J. Vanderhaeghen. Study of the interstitial cells of Cajal in infantile hypertrophic pyloric stenosis. Gastroenterology 111: 279-288, 1996[Medline].

249.   Vanderwinden, J. M., J. J. Rumessen, H. Liu, D. Descamps, M. H. De Laet, and J. J. Vanderhaeghen. Interstitial cells of Cajal in human colon and in Hirschsprung's disease. Gastroenterology 111: 901-910, 1996[Medline].

250.   Villaschi, S., and R. F. Nicosia. Paracrine interactions between fibroblasts and endothelial cells in a serum-free coculture model. Modulation of angiogenesis and collagen gel contraction. Lab. Invest. 71: 291-299, 1994[Medline].

251.   Vyas, S. K., H. Leyland, J. Gentry, and M. J. Arthur. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology 109: 889-898, 1995[Medline].

252.   Wallace, J. L., and D. N. Granger. The cellular and molecular basis of gastric mucosal defense. FASEB J. 10: 731-740, 1996[Abstract/Free Full Text].

253.   Walshe, R., P. Esser, P. Wiedemann, and K. Heimann. Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction. Br. J. Ophthalmol. 76: 550-552, 1992[Abstract].

254.   Wang, H., C. R. Keese, I. Giaever, and T. J. Smith. Prostaglandin E2 alters human orbital fibroblast shape through a mechanism involving the generation of cyclic adenosine monophosphate. J. Clin. Endocrinol. Metab. 80: 3553-3560, 1995[Abstract].

255.   Wang, J., W. Niu, Y. Nikiforov, S. Naito, S. Chernausek, D. Witte, D. LeRoith, A. Strauch, and J. A. Fagin. Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J. Clin. Invest. 100: 1425-1439, 1997[Abstract/Free Full Text].

256.   Wang, Q. P., E. Escudier, F. Roudot-Thoraval, I. Abd-Al Samad, R. Peynegre, and A. Coste. Myofibroblast accumulation induced by transforming growth factor-beta is involved in the pathogenesis of nasal polyps. Laryngoscope 107: 926-931, 1997[Medline].

257.   Ward, S. M., A. J. Burns, S. Torihashi, S. C. Harney, and K. M. Sanders. Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. Am. J. Physiol. 269 (Cell Physiol. 38): C1577-C1585, 1995[Abstract/Free Full Text].

258.   Weber, K. T., Y. Sun, and L. C. Katwa. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int. J. Biochem. Cell Biol. 29: 31-42, 1997[Medline].

259.   Wilborn, J., L. J. Crofford, M. D. Burdick, S. L. Kunkel, R. M. Strieter, and M. Peters-Golden. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J. Clin. Invest. 95: 1861-1868, 1995[Medline].

260.   Wright, N. A., C. Pike, and G. Elia. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature 343: 82-85, 1990[Medline].

261.   Xing, Z., J. Gauldie, G. Cox, H. Baumann, M. Jordana, X. F. Lei, and M. K. Achong. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101: 311-320, 1998[Abstract/Free Full Text].

262.   Yamagishi, S., K. Kobayashi, and H. Yamamoto. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. Biochem. Biophys. Res. Commun. 190: 418-425, 1993[Medline].

263.   Yamakage, A., K. Kikuchi, E. A. Smith, E. C. LeRoy, and M. Trojanowska. Selective upregulation of platelet-derived growth factor alpha  receptors by transforming growth factor beta  in scleroderma fibroblasts. J. Exp. Med. 175: 1227-1234, 1992[Abstract].

264.   Yashiro, M., Y. S. Chung, T. Kubo, F. Hato, and M. Sowa. Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br. J. Cancer 74: 1096-1103, 1996[Medline].

265.   Yee, H. F., Jr. Rho directs activation-associated changes in rat hepatic stellate cell morphology via regulation of the actin cytoskeleton. Hepatology 28: 843-850, 1998[Medline].

266.   Yoshioka, H., G. Ohshio, M. Inada, Y. Hamashima, and T. Miyake. Immunohistochemical localization of the actin in the healing stage of gastric ulcers. J. Exp. Pathol. 3: 271-280, 1987[Medline].

267.   Youngman, K. R., P. L. Simon, G. A. West, F. Cominelli, D. Rachmilewitz, J. S. Klein, and C. Fiocchi. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 104: 749-758, 1993[Medline].

268.   Zimmermann, E. M. Intestinal fibrosis in inflammatory bowel disease. Regul. Pept. Lett. VII: 60-63, 1997.

269.   Zimmermann, E. M., L. Li, Y. T. Hou, M. Cannon, G. M. Christman, and K. N. Bitar. IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): G875-G882, 1997[Abstract/Free Full Text].


Am J Physiol Cell Physiol 277(1):C1-C19
0002-9513/99 $5.00 Copyright © 1999 the American Physiological Society